Botanicals and Their Bioactive Phytochemicals for Women’s Health

Birgit M. Dietz, Atieh Hajirahimkhan, Tareisha L. Dunlap, and Judy L. Bolton

University of Illinois at Chicago/National Institutes of Health Center for Botanical Dietary Supplements, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois

Abstract

I. Introduction

A. Women's Health as a Function of Age

B. Pharmaceutical Treatments

1. Premenstrual Syndrome
2. Urinary Tract Infections
3. Pregnancy
4. Lactation
5. Menopausal Symptoms

C. Botanicals as Alternatives for Women’s Health

D. Current Approaches and Techniques in Botanical Research

1. Identification and Procurement of Plant Material
2. Identification of Bioactive Compounds
3. The Selection and Implementation of Appropriate Screening Bioassays
4. Interactions between Phytochemicals in Botanical Extracts
5. In Vivo Studies; Pharmacokinetic Profile

II. Botanicals Used by Premenopausal Women

A. Premenstrual Syndrome

1. Vitex agnus-castus (Chasteberry)
2. Angelica sinensis (Dong Quai)
3. Viburnum opulus and Viburnum prunifolium (Cramp Bark and Black Haw)
4. Zingiber officinale (Ginger)
5. Valeriana officinalis (Valerian)
6. Oenothera biennis (Evening Primrose)

B. Urinary Tract Infections

1. Vaccinium macrocarpon (Cranberry)
2. Arctostaphylos uva-ursi (Bearberry)

III. Botanicals Used during Pregnancy/Lactation

A. Nausea

1. Zingiber officinale (Ginger)

B. Lactation

1. Trigonella foenum-graecum (Fenugreek)
2. Silybum marianum (Milk Thistle)

IV. Botanicals Used by Menopausal Women

A. Menopausal Symptoms

1. Serotonergic Mechanism
   a. Actaea/Cimicifuga racemosa (black cohosh)
   b. Valeriana officinalis (valerian)
2. Estrogenic Mechanism. ................................................................. 1041
   a. Isoflavones. ........................................................................... 1041
      i. Glycine max (Soy). ............................................................. 1041
      ii. Trifolium pratense (Red Clover). ..................................... 1042
      iii. Fueraria lobata (Kudzu). ................................................ 1042
      iv. Eriosema laurentii (Guinea-Bissau). .............................. 1043
   b. Humulus lupulus (hops). .......................................................... 1043
   c. Glycyrrhiza species (licorice). ............................................... 1043
   d. Rheum rhaponticum (rhubarb). ............................................ 1045
   e. Vitex agnus-castus (chasteberry). ......................................... 1045
   f. Linum usitatissimum (flaxseed). ............................................. 1046
   g. Epimedium species (horny goat weed). ................................. 1046
   h. Lepidium meyenii (maca). ..................................................... 1046
      i. Oenothera biennis (evening primrose). .............................. 1047
   j. Medicago sativa (alfalfa). ...................................................... 1047
3. Unknown Mechanism. ............................................................... 1047
   a. Dioscorea villosa (wild yam). ............................................... 1047
   b. Angelica sinensis (dong quai). ............................................... 1047

B. Osteoporosis ........................................................................... 1048
   1. Isoflavones. ........................................................................ 1048
   2. Others. ................................................................................. 1048

V. Botanicals for Breast Cancer Prevention .......................................... 1048
   A. Hormonal Pathway ................................................................. 1049
   B. Chemical Pathway ................................................................. 1049
   C. Inflammatory Pathway ............................................................. 1049
   D. Epigenetic Pathway ................................................................. 1049
   E. Isoflavone-containing Botanicals (Red Clover, Soy) ................. 1049
      1. Hormonal Pathway. ............................................................. 1050
      2. Chemical Pathway. ............................................................. 1053
      3. Inflammatory Pathway. ........................................................ 1054
      4. Epigenetic Pathway. ............................................................. 1055
   F. Humulus lupulus (Hops) ........................................................ 1056
      1. Hormonal Pathway. ............................................................. 1056
      2. Chemical Pathway. ............................................................. 1057
      3. Inflammatory Pathway. ........................................................ 1057
      4. Epigenetic Pathway. ............................................................. 1058
   G. Glycyrrhiza Species (Licorice) ............................................... 1058
      1. Hormonal Pathway. ............................................................. 1058
      2. Chemical Pathway. ............................................................. 1058
      3. Inflammatory Pathway. ........................................................ 1059
      4. Epigenetic Pathway. ............................................................. 1059
   H. Silybum marianum (Milk Thistle) ........................................... 1059
      1. Hormonal Pathway. ............................................................. 1059
      2. Chemical Pathway. ............................................................. 1060
      3. Inflammatory Pathway. ........................................................ 1060
      4. Epigenetic Pathway. ............................................................. 1060

ABBREVIATIONS: AbRR, arylhydrocarbon receptor; ARE, antioxidant response element; BaP, benzo(a)pyrene; BGF, bioactivity guided fractionation; BW, body weight; CNS, central nervous system; COX-2, cyclooxygenase 2; DMBA, 7,12-dimethylbenz[a]anthracene; DNMT, DNA methyltransferase; E2, 17β-estradiol; ER, estrogen receptor; ERE, estrogen response element; EROD, ethoxyresorufin-O-deethylase; G. glabra, Glycyrrhiza glabra; G. inflata, Glycyrrhiza inflata; G. uralensis, Glycyrrhiza uralensis; HER2, human epidermal growth factor 2; HT, hormone therapy; 5-HT, 5-hydroxytryptamine (serotonin); IC50, concentration associated with 50% inhibition of the maximal activity; IKKα/β, inhibitor of nuclear factor kappa-B kinase subunit alpha/beta; IL, interleukin; iNOS, inducible nitric oxide synthase; IX, isoaxanthohumol; Keap1, Kelch-like ECH-associated protein 1; LC-MS/MS, liquid chromatography coupled with tandem mass spectrometry; LPS, lipopolysaccharide; MS, mass spectrometry; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NQO1, NAD(P)/H, quinone oxidoreductase 1; NrF2, nuclear factor (erythroid-derived 2)-like 2; NSAID, nonsteroidal anti-inflammatory drug; NMR, nuclear magnetic resonance; PGF2, prostaglandin E2; PMS, premenstrual syndrome; 6-PN, 6-prenylnaringenin; 8-PN, 8-prenylnaringenin; SSRI, selective serotonin reuptake inhibitor; TCD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TPA, 12-O-tetradecanoylphorbol-13-acetate; UTI, urinary tract infection; XH, xanthohumol; XRE, xenobiotic response element.
I. Introduction

A. Women’s Health as a Function of Age

Women’s health and wellbeing are profoundly affected by hormone levels, which can vary dramatically with age, as shown for estrogen in Fig. 1. In addition, older women are more susceptible to illnesses such as cancer, cardiotoxicity, and neurodegenerative diseases (Abouzahr, 2014; de la Cruz et al., 2014; Alzheimer’s Association, 2014). These illnesses are stimulated by inflammation as well as exogenous and endogenous stressors (Clark and Vissel, 2013; Wright et al., 2013; Djaldetti and Bessler, 2014; Ren and Xu, 2015). Hormone balance is crucial to stabilizing women’s physiology, because hormones control vital biological functions including cardiovascular, respiratory, digestive, reproductive, cerebral, and immune systems. The two main sex hormones in women are estrogen and progesterone (Fig. 2). Estrogen is synthesized in the ovaries and adipose tissue and is responsible for secondary sex characteristics and cell growth. Progesterone balances estrogen’s proliferative effect. Hormonal imbalance can lead to several health issues such as obesity, cardiovascular disease, autoimmune disease, breast cancer, and osteoporosis. It is now recognized that woman’s healthcare must take aging and hormone balance into consideration for quality of life and prevention of disease (Morris and Currie, 2013). However, many women have lost faith in conventional pharmaceuticals because of confusion in recommendations as well as distrust in the medical system that seems to view natural aging and menopause in particular as diseases (Taylor, 2015). This review will focus on women’s health botanicals as natural alternatives to traditional pharmaceutical therapies used by premenopausal, menopausal, and postmenopausal women.

B. Pharmaceutical Treatments

1. Premenstrual Syndrome. A wide range of pharmacological approaches are available to treat premenstrual syndrome (PMS), including oral contraceptives (birth control pills), nonsteroidal anti-inflammatory drugs (NSAIDs), dopamine agonists, diuretic agents, and selective serotonin reuptake inhibitors (SSRIs) (Kelderhouse and Taylor, 2013; Imai et al., 2015) (Fig. 3). Birth control pills are effective remedies for premenopausal women to relieve menstrual cramping as well as preventing pregnancy. They suppress ovulation and thin the endometrial lining, which reduces menstrual fluid volume along with prostaglandin levels, which in turn decreases the pain associated with uterine
contractions (Creatsas et al., 1990; Zahradnik et al., 2010). Side effects include nausea, water retention, and weight gain and birth control pills may not be suitable for some women, especially those wanting to become pregnant. NSAIDs such as ibuprofen (Fig. 3) reduce myometrial activity by inhibiting prostaglandin synthesis and reducing vasopressin secretion; however, the failure rate is often 25% and many women cannot tolerate NSAIDs due to side effects that can include bleeding, ulcers, vomiting, and diarrhea (Zahradnik et al., 2010). SSRIs have demonstrated efficacy for treating PMS in randomized placebo-controlled clinical trials (Marjoribanks et al., 2013); however, significant side effects have been reported particularly in the beginning of treatment including headache, nausea, insomnia, fatigue, diarrhea, dizziness, sexual side effects, and reduced concentration (Freeman, 2010).

2. Urinary Tract Infections. Most uncomplicated urinary tract infections are caused by bacteria that enter the urethra and then the bladder where the infection develops (Little et al., 2010). Women tend to have more frequent urinary tract infections (UTIs), because their urethra is shorter and closer to the anus than in men. UTIs are usually treated with sulfa drugs and antibiotics (Fig. 4). The major problem with excessive antibiotic use, particularly to treat recurring UTIs, is development of drug-resistant bacteria (Nickel, 2007).

3. Pregnancy. The most common adverse symptom associated with pregnancy is morning sickness. Over the years there have been several reports of teratogenic adverse drug reactions associated with pregnancy medications (Saunders and Saunders, 1990). The most sensational of these was the stunted limb growth and severe birth abnormalities associated with exposure to thalidomide (Fig. 5). Similar severe birth defects appeared with the development of secondary sex characteristics in the children of women exposed in utero to diethylstilbestrol (Fig. 5). These sobering examples help explain why women are very reluctant to take prescription drugs for morning sickness. Some recent data may indicate that drugs such as metoclopramide (Fig. 5) may be safe and offer some relief to women when morning sickness severely impacts their quality of life (Lee and Saha, 2011). For example, a recent Danish study on 40,000 women taking metoclopramide (reglan) during pregnancy showed no statistically significant increase in birth defects or miscarriages (Pasternak et al., 2013). However, likely because of the tragic history of drugs prescribed for morning sickness as well as the recommendation by most doctors to avoid prescription drugs entirely during pregnancy, women often look for natural alternatives to control symptoms.

Fig. 1. Botanicals women take as a function of age. The popularity of botanical dietary supplements varies as a function of age, hormone levels, and usage.

Fig. 2. Structures of estradiol and progesterone.
4. Lactation. The most frequent cause of breastfeeding failure is decreased milk production. There are a number of prescription drugs that stimulate lactation including metoclopramide (reglan, Fig. 5), domperidone (motilium, motilidone, Fig. 6), and sulpiride (dolmatil, sulparex, Fig. 6) (Zuppa et al., 2010; Rowe et al., 2013). For example, a modest increase in breast milk volume (100 ml/day) has been reported in mothers of preterm infants given domperidone (Donovan and Buchanan, 2012). However, side effects have been reported with prescription galactagogues, including severe depression, nausea, gastric upset, and diarrhea, and along with the fear that these drugs might contaminate breast milk, many women prefer natural galactagogues, which are perceived as safe (Gabay, 2002; Marcellin and Chantry, 2015).

5. Menopausal Symptoms. Hot flashes and night sweats are the most commonly experienced menopausal symptoms contributing to adverse quality of life (Nelson, 2008). The gold standard of care for menopausal symptoms before the release of the Women’s Health Initiative was hormone therapy (HT). Oral conjugated equine estrogens [i.e., estradiol (Fig. 2), equilin (Fig. 7), equilenin] were the most commonly used estrogen formulations either alone or in combination with a progestin (Fig. 7) (Bhavnani and Stanczyk, 2014; Stanczyk and Bhavnani, 2014). Since the release of the Women’s Health Initiative report in 2002 (Rossouw et al., 2002) and the Million Women study in 2003 (Beral and Million Women Study Collaborators, 2003), women have been discouraged from using traditional HT because of the increased risk of breast cancer, coronary heart disease, stroke, and pulmonary embolism within the estrogen plus progestin arm and increased risk of stroke within the estrogen arm (Brass, 2004; Chlebowski et al., 2013; Manson and Branch, 2014). Despite recent analysis that suggests that women benefit from early initiation of HT with no significant increased breast cancer risk, women still associate HT with these detrimental side effects (Schierbeck et al., 2012; Lacey, 2014). Nonhormonal therapies are also prescribed such as antidepressants, which may act through serotonergic mechanisms. The data suggest that the SSRIs, serotonin-norepinephrine reuptake inhibitors, have efficacy; however, the relief from hot flashes and night sweats are much less than observed with traditional HT and side effects and cost may restrict use for most women (Nelson et al., 2006; Shen and Stearns, 2009).

C. Botanicals as Alternatives for Women’s Health

Largely as the result of adverse effects reported for prescription medications for women’s health (i.e., Women’s Health Initiative and increased breast cancer risk), women are frequently turning to botanicals because they are perceived as safe despite the lack of supporting rigorous scientific documentation on either safety or efficacy (North American Menopause Society, 2004, 2011; Lloyd and Hornsby, 2009; Hajirahimkhan et al., 2013a; Garcia-Cazarin et al., 2014; Lindstrom et al., 2014; van Breemen,
2015). The sales of herbal dietary supplements reached 6.4 billion in 2014, with women as the major users taking these botanicals for a variety of ailments (Blumenthal et al., 2015). The rank order in sales of women’s health botanicals presented in Table 1 and Fig. 1 shows the popularity of botanicals as a function of a woman’s age. However, scientific data about the efficacy of botanicals in women’s health and their role in preventing diseases is scarce, and regulations for biological and chemical standardization of these botanicals before marketing is lacking (Snelten et al., 2012; Dietz and Bolton, 2013; Hajirahimkhan et al., 2013a). One of the major problems with clinical research on botanical dietary supplements is the large placebo effect, which is often observed particularly with botanicals which affect the CNS (Nedrow et al., 2006; Geller et al., 2009; Wong et al., 2009). These placebo effects often lead to equivocal and nonsignificant effects, making recommendations on efficacy difficult. In fact, the placebo effect could explain the increase in use of botanical dietary supplements especially as the population ages. Older women are also more likely to use botanicals because they have increased health needs and probably more disposable income.

D. Current Approaches and Techniques in Botanical Research

Current research in mechanism of action of botanicals involves a multifaceted approach including phytochemical, biological, and analytical techniques (van Breemen, 2015) (Fig. 8). Numerous challenges are encountered including the 1) identification and procurement of reproducible plant material, 2) the identification of bioactive chemical compounds, 3) the selection and implementation of appropriate screening bioassays, 4) potential interactions between the phytoconstituents in a botanical extract, and 5) the analysis of in vivo effects including their metabolism and distribution profile.

1. Identification and Procurement of Plant Material. Commercial botanicals used for women’s health have a long history of traditional use with little scientific evidence of efficacy, safety, or other potential health benefits. For robust scientific studies on these botanicals it is crucial to have a reliable source for the procurement of plant material, because many factors such as plant location, temperature, harvest time, as well as postharvest processing steps, such as drying, can have significant impact on the phytochemical profile of the plant material (Pferschy-Wenzig and Bauer, 2015). In addition, correct authentication of the plant material is essential. Misidentifications can occur due to name similarities. For example, in a dietary supplement formulation the roots of *Stephania tetrandra* were inadvertently substituted with the roots of *Aristolochia fangchi* because of the close similarity of the Chinese names leading to an endemic nephropathy including end-stage kidney failure (Vanherweghem, 1998; Dietz and Bolton, 2007). Moreover, misidentification can occur, when the pharmacologically used plant parts, for example roots, of similar species are undistinguishable or if the plant part is provided as powdered material (Dunlap et al., 2015; Simmler et al., 2015a). A visual differentiation of the plant species is usually possible when the whole plant is examined; however, other pharmacognostic methods become necessary for the individual plant part (Simmler et al., 2015b). The botanical integrity may be analyzed by microscopy using taxonomic keys. In many cases, this might not be sufficient to unequivocally identify the raw plant material or powder and in these cases DNA barcoding might be required. Licorice is an example in which DNA barcoding became necessary to unequivocally identify the different species. The roots of the three
medicinally used licorice species, *Glycyrrhiza uralensis*, *G. glabra*, and *G. inflata* are very similar and difficult to distinguish although they are quite different chemically and biologically (Kondo et al., 2007b). The use of DNA barcoding made it possible to differentiate these species and to even distinguish hybrids of these plants (Simmler et al., 2015a). After the preparation of botanical extracts, an array of analytical methods are available to perform phytochemical analyses [e.g., thin-layer chromatography, liquid chromatography coupled with tandem mass spectrometry, LC-MS/MS and nuclear magnetic resonance (NMR)] to unambiguously identify the plant material used for the preparation of the extract (Simmler et al., 2015b).

### 2. Identification of Bioactive Compounds

To obtain efficacious and safe plant-based remedies, it is essential to identify the bioactive and toxic phytoconstituents as well as to describe their mechanism of action (van Breemen, 2015). For some herbal dietary supplements the major bioactive constituents for the indicated medical use are known. For example, the observed in vitro estrogenic activity of soy and red clover extracts are mainly due to the isoflavones, genistein and biochanin A (Overk et al., 2005; Hajirahimkhan et al., 2013a) (Fig. 24). However, other botanicals have been medicinally used for years

### TABLE 1

<table>
<thead>
<tr>
<th>Rank</th>
<th>Latin Name</th>
<th>Common Name</th>
<th>Use</th>
<th>Reported Mechanism</th>
<th>Proposed Phytochemical</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.</td>
<td><em>Vaccinium macrocarpon</em></td>
<td>Cranberry</td>
<td>UTI</td>
<td>Bacterial adhesion</td>
<td>Proanthocyanidins</td>
</tr>
<tr>
<td>4.</td>
<td>Actaea/Cimicifuga racemosa</td>
<td>Black cohosh</td>
<td>Menopause</td>
<td>Serotonin</td>
<td>N-methylserytonin</td>
</tr>
<tr>
<td>5.</td>
<td><em>Linum usitatissimum</em></td>
<td>Flaxseed</td>
<td>Menopause&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Estrogen</td>
<td>Enterodiol/lenterolactone</td>
</tr>
<tr>
<td>6.</td>
<td><em>Valeriana officinalis</em></td>
<td>Valerian</td>
<td>Menopause/PM&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Serotonin</td>
<td>Valerenic acid</td>
</tr>
<tr>
<td>12.</td>
<td><em>Silybum marianum</em></td>
<td>Milk thistle</td>
<td>Lactation&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Prokinetic</td>
<td>Gingerols/shogaols</td>
</tr>
<tr>
<td>27.</td>
<td><em>Lepidium meyenni</em></td>
<td>Maca</td>
<td>Menopause</td>
<td>Estrogen</td>
<td>Phytosteros</td>
</tr>
<tr>
<td>28.</td>
<td><em>Trigonella foenuum-graecum</em></td>
<td>Fenugreek</td>
<td>Lactation</td>
<td>Estrogen</td>
<td>Diosgenin, apigenin, luteolin</td>
</tr>
<tr>
<td>29.</td>
<td><em>Isoflavones</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glycine max</td>
<td>Soy</td>
<td>Menopause/bone</td>
<td>Estrogen</td>
<td>Genistein, daidzein -&gt; equol</td>
</tr>
<tr>
<td></td>
<td>Trifolium pratense</td>
<td>Red clover</td>
<td>Menopause/bone</td>
<td>Estrogen</td>
<td>Biochanin A -&gt; genistein</td>
</tr>
<tr>
<td></td>
<td><em>Pueraria lobata</em></td>
<td>Kudzu</td>
<td>Menopause</td>
<td>Estrogen</td>
<td>Puerarin -&gt; daidzein</td>
</tr>
<tr>
<td></td>
<td><em>Eriogona lauritii</em></td>
<td>Guinea-bissau</td>
<td>Menopause</td>
<td>Estrogen</td>
<td>Lupinalin A</td>
</tr>
<tr>
<td>37.</td>
<td><em>Onothera biennis</em></td>
<td>Evening primrose</td>
<td>Menopause/PM&lt;sup&gt;e&lt;/sup&gt;</td>
<td>Estrogen</td>
<td>y-linolenic acid</td>
</tr>
</tbody>
</table>

**Not ranked (out of top 40)**

<table>
<thead>
<tr>
<th>Rank</th>
<th>Latin Name</th>
<th>Common Name</th>
<th>Use</th>
<th>Reported Mechanism</th>
<th>Proposed Phytochemical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angelica sinensis</td>
<td>Dong quai</td>
<td>Menopause/PM</td>
<td>SERM/unknown</td>
<td>Ligustilide</td>
<td></td>
</tr>
<tr>
<td>Arcostachyphos uva-ursi</td>
<td>Bearberry</td>
<td>UTI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dioscorea villoa</td>
<td>Wild yam</td>
<td>Menopause/PM</td>
<td>Estrogen</td>
<td>Diosgenin</td>
<td></td>
</tr>
<tr>
<td>Glycyrrhiza species</td>
<td>Licorice</td>
<td>Menopause</td>
<td>Estrogen</td>
<td>Liquiritigenin</td>
<td></td>
</tr>
<tr>
<td>Humulus lupulus</td>
<td>Hops</td>
<td>Menopause&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Estrogen</td>
<td>Xanthohumol -&gt; 8-PN</td>
<td></td>
</tr>
<tr>
<td>Medicago sativa</td>
<td>Alfalfa</td>
<td>Menopause</td>
<td>Estrogen</td>
<td>Coumestrol</td>
<td></td>
</tr>
<tr>
<td>Rheum rhaponticum</td>
<td>Rhubarb</td>
<td>Menopause</td>
<td>Estrogen</td>
<td>Piceatannol</td>
<td></td>
</tr>
<tr>
<td>Vitex agnus-castus</td>
<td>Chasteberry</td>
<td>Menopause/PM</td>
<td>CNS/estrogen</td>
<td>Apigenin/penduletin</td>
<td></td>
</tr>
<tr>
<td>Viburnum opulus/prunifolium</td>
<td>Cramp bark/black haw</td>
<td>PMS</td>
<td>Antispasmodic</td>
<td>Scoletinin</td>
<td></td>
</tr>
</tbody>
</table>

SERM, selective estrogen receptor modulator.

<sup>a</sup>More commonly used for lipid lowering and anti-inflammatory.

<sup>b</sup>More commonly used as a sedative.

<sup>c</sup>More commonly used for anti-inflammatory and immune modulation.

<sup>d</sup>More commonly used for liver detoxification.

<sup>e</sup>More commonly used to treat eczema.

<sup>f</sup>Alphabetical order.

---

Fig. 8. Integration of phytochemistry, bioassay, and pharmacokinetics to standardize botanicals to bioactive phytochemicals.
without a clear knowledge of the bioactive constituents (Qiu et al., 2014). Extracts of the roots of black cohosh (Actaea/Cimicifuga racemosa) are an example of a plant that has been standardized to a lead compound, the triterpene, 23-epi-26-deoxyactein (formerly 27-deoxyacetin) (Chen et al., 2002); however, there is no evidence that the triterpenes have any effect on menopausal symptom relief (Qiu et al., 2014). The active compounds in black cohosh have not been clearly identified, although, as discussed in section IV.A.1, \(N_\omega\)-methylserotonin has been isolated as a potential serotonin receptor agonist (Fig. 9) (Powell et al., 2008). In preclinical and clinical investigations of botanicals, it is desirable to use extracts that have been chemically and biologically standardized to the active compounds to analyze a safe and efficacious dose for these botanical products. In addition, once the bioactive compounds are known optimal extraction procedures (choice of extraction solvent, defatting) can be used to enrich the active compounds. The comparative analysis of many clinical studies with botanical extracts is often problematic, because various extracts with different solvents are used and therefore comparisons or conclusions are difficult to draw (Qiu et al., 2014; van Breemen, 2015).

When pharmacological/clinical studies are done with individual phytoconstituents, the purity and appropriate analysis methods should be reported (Betz et al., 2011; Pauli et al., 2014). This is especially important when easily degradable compounds are analyzed. This has been a particular problem with studies on Angelica sinensis, because the proposed bioactive compound Z-ligustilide is particularly unstable (Dietz et al., 2008) (Fig. 10). In these cases quality control analysis of these compounds may have to be performed at regular intervals throughout the studies (Schinkovitz et al., 2008). In this review, we put higher emphasis on studies that used well-analyzed bioactive compounds and standardized extracts for pharmacological and clinical investigations.

3. The Selection and Implementation of Appropriate Screening Bioassays. Because of the complex nature of botanical extracts with a multitude of phytoconstituents, robust and medium to high-throughput assays that tolerate crude extracts or fractions/partitions are desirable for the characterization of bioactive and toxic compounds (Piersen et al., 2004). Various problems might occur during the biological screening process of natural products. These issues were recently reviewed in more detail (Sink et al., 2010; Thorne et al., 2010; Bisson et al., 2016). Briefly, some phytochemicals may give false-positive results because of nonspecific enzyme or protein interactions, formation of aggregates that may bind to protein targets, detergent-like effects, membrane disruption, cytotoxicity in cell based assays, precipitation of an analyte, and interference with detection methods, such as ultraviolet-, luminescence-, or fluorescence detection (Piersen et al., 2004; Bisson et al., 2016). Therefore, modifications of the bioassay, removal of interfering compounds, such as fatty acids, additional controls, use of additional computational methods, inclusion of literature data, and additional bioassays to test for interference or functional activity using different detection systems might be necessary to ensure functional and meaningful biological results (Piersen et al., 2004; Bisson et al., 2016). Ultimately, in vivo tests will be required to analyze the clinical potential of these phytochemicals/botanical extracts. Often not one single compound is responsible for the activity of the extract, but rather several phytoconstituents that lead to the observed overall activity through interactive processes, e.g., additive, synergistic, or antagonistic effects (Piersen et al., 2004; Gertsch, 2011). In general, to identify bioactive compounds in multicomponent extract mixtures a variety of different approaches might be used as outlined below.

i. Bioactivity guided fractionation (BGF) tries to connect analytical techniques with a biological/ biochemical assay, to isolate substances of biological relevance (Weller, 2012; van Breemen, 2015). BGF aims to identify the phytoconstituents that are responsible for a certain bioactivity of the botanical extract (Agarwal et al., 2014). Different chromatographic techniques may be used to separate the extract into fractions, which will be tested in a particular bioassay, and the most active fractions will be further separated (Weller,
An example is the fractionation of a black cohosh extract using the 5-HT$_7$ receptor binding activity of the black cohosh fractions as the bioassay target (Powell et al., 2008). Subsequently, the potent, 5-HT$_7$-ligand, $N_v$-methylserotonin (Fig. 9), was identified in the active black cohosh fractions (Fig. 11). A parallel detection of possible known compounds by LC-MS/MS using databases or NMR and structure elucidation in the active fractions is important to avoid isolation of known compounds (dereplication) (Weller, 2012; Wolfender et al., 2015). The compounds that have been isolated or identified through BGF can also be tested in several other assays including functional cell based assays that generally show less interference with fatty acids or chlorophyll leading to false-positive results. Also, using human cell culture models has the advantage that they might better predict human-compound interactions before preclinical and clinical trials (Nierode et al., 2016). However, often BGF of a botanical extract does not lead to one strongly active compound but to several weakly active compounds due to possible interactive/synergistic processes (Piersen et al., 2004). Another reason might be that the isolated, purified compounds might be unstable, such as $Z$-ligustilide from Angelica sinensis discussed above (Fig. 10); however, these compounds may be stabilized in the whole plant matrix (Schinkovitz et al., 2008).

**ii. Mass spectrometry (MS) screening** might present a higher-throughput alternative than BGF (van Breemen, 2015), because MS-based screening eliminates the laborious process of fractionation by using affinity extraction steps for example (e.g., magnetic bead affinity MS-based screening) (van Breemen, 2015; Wolfender et al., 2015). The bound ligands or compounds that lead to a reaction with the analyzed enzyme can immediately be characterized by MS (van Breemen, 2015; Wolfender et al., 2015). In addition to LC-MS/MS, biological assays can also be coupled with planar chromatographic methods, such as thin layer chromatography (bioautography) (Wolfender et al., 2015). This method has often been used for the identification of antibacterial, antifungal, and antioxidant or enzyme inhibiting compounds in the target-directed isolation of active phytoconstituents of natural products (Dewanjee et al., 2015). The advantage of these online biological identification methods are that they are faster and require less plant material or botanical extracts. However, to verify the activity and for mechanism of action studies it is necessary to have the purified fully characterized compound.

**iii. Compound-directed analysis.** Many different methods, mainly LC-MS/MS and NMR techniques, enable the identification of several phytoconstituents "metabolite profiling" in a complex mixture with subsequent data mining tools (Wolfender et al., 2015). Several metabolomic techniques recently advanced this approach and were reviewed in detail elsewhere (Fillet and Frederich, 2015; Wolfender et al., 2015). This approach puts the emphasis on the identification of phytoconstituents in a plant or microorganism. After dereplication of known compounds, unknown constituents need to be isolated from the plant or other matrices. Subsequently, these compounds can be tested in several bioassays. Unanticipated effects might be discovered by this method. Alternatively, if a targeted biological examination is desired, this might lead to a quicker discovery of novel and active phytochemicals (Wu et al., 2015a).

**4. Interactions between Phytochemicals in Botanical Extracts.** Because botanical extracts are multicomponent mixtures, the different phytoconstituents might influence each other, leading to additive, synergistic, and/or antagonistic effects (Wagner, 2011; Pelkonen et al., 2014). Therefore, the activity of the extracts might not be solely the responsibility of one or two compounds, but a multitude of compounds might be involved. Because of the difficulty in analysis of multiple interactions between the phytoconstituents
in botanical extracts, these effects have not been well studied and much more research is needed in this field (Gertsch, 2011). Synergistic or antagonistic activities of phytoconstituents can be analyzed, for example by the isobol method or the Chou-Talalay combination index (Chou and Talalay, 1984). By using these methods, synergistic effects of 6-gingerol in a ginger extract (Fig. 15) on inhibition of prostate cancer cell growth and synergistic antimicrobial effects of constituents in _Hydrastis canadensis_ have been demonstrated (Junio et al., 2011; Brahmbhatt et al., 2013). Although some investigations have analyzed synergistic or antagonistic effects of phytochemicals with drugs or other botanicals (Einbond et al., 2006), studies to analyze the interactions of phytochemicals in one botanical used for women’s health are mostly lacking. Other interactions between phytochemicals in a plant extract are possible, such as stabilization of one compound by other compounds in an extract and facilitation of absorption and therefore higher bioavailability by compounds in the extract matrix rather than isolated compounds. In general, the complexity of botanical extracts is often seen as an advantage and as a promising strategy to manage complex chronic diseases, such as neurodegenerative disorders through targeting multiple pharmacological targets by a complex extract (Hopkins, 2008; Li et al., 2011). This is in contrast to the classic paradigm of single target-single drug and requires appropriate analysis of influences on network pharmacology using genomic or proteomic approaches combined with functional assays (Pelkonen et al., 2014).

5. In Vivo Studies; Pharmacokinetic Profile. After bioactive extracts standardized to the phytochemical and potential toxic constituents have been established, _in vivo_ studies have to be performed (van Breemen, 2015). A limiting factor of the clinical bioactivity of phytoconstituents is often the extensive metabolism in vivo. Many active botanical compounds are polyphenols and therefore prone to extensive metabolism. For example, liquiritigenin (Fig. 27) from licorice and curcumin from turmeric form multiple glucuronides (Ganesan et al., 2015; Hajirahimkhan et al., 2015). In the case of curcumin, efforts are underway to improve its bioavailability and therefore enhance its clinical efficacy (Ganesan et al., 2015). The _in vivo_ studies will give essential information about the metabolism profile, pharmacokinetic, and distribution profile. In addition, the animal models have to be selected to test for the desired efficacy and safety. For example, the estrogenic activity of plant extracts can be evaluated with immature Sprague-Dawley rats that do not produce estradiol and with ovariectomized Sprague-Dawley rats (Overk et al., 2007, 2008). These animals are very susceptible to compounds with estrogenic activity, such as phytoestrogens, and would show an increase in uterine weight after a few days of estrogenic treatment. After the _in vivo_ activity of the botanical extracts and their bioactive constituents have been determined and the induction/inhibition profile of human P450 enzymes has been established in animal models, ideally double-blind, placebo-controlled, randomized human clinical trials should be performed with the standardized extract or well described phytochemical to ensure clinical efficacy and safety (van Breemen, 2015).

To fulfill all these steps necessary for the analysis of pharmacological mechanisms of botanicals and their standardization, a multidisciplinary team of researchers is necessary. An example of a well-established team is the UIC/NIH Center for Botanical Dietary Supplements Research (UIC Botanical Center), which has been investigating the safety and mechanisms of action of botanical dietary supplements consumed by women since 1999 for the purpose of maintaining good health and quality of life, especially during the transition to and through menopause (Farnsworth et al., 2008). This Botanical Center involves a synergistic team of multidisciplinary investigators with complementary expertise who are organized into three Projects (Phytochemistry/standardization, Biological evaluation, Metabolism and safety) and three research Cores (Botanical, Bioassay, Chemical) (Fig. 12). The organization is very similar to the general scheme shown in Fig. 8.

II. Botanicals Used by Premenopausal Women

A. Premenstrual Syndrome

Menstrual cramps are a very common ailment in premenopausal women experienced by approximately 50% of women starting with first menses (Dawood, 2006). Pain usually starts within hours of menstrual bleeding and peaks during the heaviest flow on the second or third day of the cycle. Cramps can worsen as women age due to hormone imbalance and other conditions associated with this including uterine fibroids and adenomyosis. These cramps are caused by the release of prostaglandins that induce spasms in the uterine muscle. As a result, botanicals with smooth muscle relaxing properties could be effective antispasmodic agents (Park et al., 2014; van Andel et al., 2014). Botanicals traditionally used to treat menstrual disorders are reviewed below.

1. _Vitex agnus-castus_ (Chasteberry). Chasteberry is obtained from the dried ripe fruit of the chaste tree and has been used as a women’s health botanical since ancient Greece (Wuttke et al., 2003). One mechanism of action could be through the dopamine receptors, which decrease thyrotropin releasing hormone and prolactin levels, alleviating PMS symptoms (Meier et al., 2000; Tamagno, 2009). Chasteberry has also been shown to have hormone modulating properties in vitro that may play a role in regulating PMS symptoms (Girmian et al., 2003; Lloyd and Hornsby, 2009). Weak binding affinity for the estrogen receptors and modulation of hormone sensitive genes have been reported in vitro (Liu et al., 2001, 2004; Hajirahimkhan et al., 2013a) as well as estrogenic effects.
on the uterus in rat models (Ibrahim et al., 2008). An alternative mechanism as an opiate receptor agonist has also been reported (Webster et al., 2006, 2011; Chen et al., 2011). A number of phytochemicals have been isolated from chasteberry including several flavonoids and linoleic acid, which could be responsible for the biological activities (Fig. 13) (Chen et al., 2011; Webster et al., 2011). Apigenin and penduletin in particular have been identified as weak ER$\beta$-selective ligands (Fig. 13) (Jarry et al., 2003; Hu et al., 2007b), although apigenin is present in numerous plants. A small randomized, double-blind, placebo-controlled trial (67 Chinese women) did show significant efficacy of chasteberry compared with placebo in the treatment of moderate to severe PMS (Ma et al., 2010). Other small placebo controlled trials also suggested benefit; however, the placebo effect was large, which is often seen in clinical trials with effects on the CNS (Berger et al., 2000; Schellenberg, 2001, 2012; He et al., 2009; Zamani et al., 2012). These trials were of short duration and safety data were lacking. The German Commission E approved the use of chasteberry for PMS and chasteberry has the most convincing clinical data out of all of the botanicals for efficacy in the treatment of PMS (Freeman, 2010).

2. Angelica sinensis (Dong Quai). Dong quai or danggui is the dried root of Angelica sinensis, which is commonly used in traditional Chinese medicine to promote blood circulation and treat menstrual disorders such as dysmenorrhea as well as other women’s health issues (Wu and Hsieh, 2011; Chen et al., 2013). It has been shown that a bioactive component of dong quai, Z-ligustilide (Fig. 10), inhibits the contraction of isolated rat uterus in a dose-dependent manner and improves microcirculation, suggesting it might be responsible for the antispasmodic effects of dong quai (Du et al., 2006). Ligustilide also has anti-inflammatory effects, which could contribute to the mechanisms of relief of menstrual symptoms (Su et al., 2011). Whether dong quai has estrogenic activity is controversial, and no estrogenic compounds have been isolated to date (Piersen, 2003; Hajirahimkhani et al., 2013a). Finally, there are no randomized, placebo-controlled, clinical trials evaluating the efficacy of dong quai for PMS.

3. Viburnum opulus and Viburnum prunifolium (Cramp Bark and Black Haw). Cramp bark and black haw are two species of viburnum that are often used as uterine relaxants and antispasmodics. Animal studies have suggested that both species have antispasmodic effects on the uterus and experiments with human uterine tissue also showed a relaxant effect (Jarboe et al., 1966; Nicholson et al., 1972; Cometa et al., 2009). Scopoletin could be responsible for the smooth muscle antispasmodic activity of viburnum (Fig. 14) (Jarboe et al., 1967; Nicholson et al., 1972). There are no randomized, placebo-controlled, clinical trials evaluating the efficacy of viburnum for PMS.

4. Zingiber officinale (Ginger). The rhizome of the ginger plant has been used for centuries as a spice and a condiment as well as for medicinal properties, particularly for anti-inflammatory and immune modulating properties (Ali et al., 2008). Ginger may also be effective at reducing PMS symptoms. More than 60 active compounds have been identified in ginger, including gingerols, shogaols, and zingerone (Fig. 15) (Baliga et al., 2011). Ginger and its bioactive compound zingerone have reported antispasmodic activities (Fig. 15) (van Andel et al., 2014; Ahmad et al., 2015). There are some reports of estrogenic activities for ginger, although other studies have shown no effect (Kim et al., 2008; Kumar et al., 2015). A small trial suggested that ginger (250 mg, 4 times daily, for three days from the start of the menstrual period) was as effective as NSAIDs at reducing period pain (Ozgoli et al., 2009). A few other small trials in young women have also shown positive effects for PMS (Kashefi et al., 2014, 2015).
5. Valeriana officinalis (Valerian). The roots and rhizomes of valerian have been used for centuries primarily for tranquilizing/sedative properties as well as for PMS (Jarema, 2008). Over 150 phytochemicals have been identified in valerian, including pyridine alkaloids and organic acids such as valerenic acid (Fig. 16) (Patocka and Jaki, 2010). The antispasmodic effects of valerian have been demonstrated in vitro and in vivo (Occhiuto et al., 2009). A double-blind, placebo-controlled, randomized clinical trial with 100 young women receiving 255 mg three times daily for 3 days at the beginning of the menstrual cycle for two consecutive cycles showed a significant reduction in the severity of pain (Mirabi et al., 2011). No adverse effects were reported in the valerian-treated group, which supports literature evaluations of safety (Kelber et al., 2014).

6. Oenothera biennis (Evening Primrose). The oil from the seeds of evening primrose are high in fatty acids, including γ-linolenic acid (Montserrat-de la Paz et al., 2014) (Fig. 17). Polyphenolic compounds are also present, including gallic acid and chatechin, which could be responsible for antioxidant effects (Wettasinghe et al., 2002) (Fig. 17). A double-blind randomized clinical trial with 40 young women receiving either femicomfort (evening primrose, vitamins B6 and E) or placebo for two menstrual cycles concluded that evening primrose was effective in relieving PMS symptoms (Kashani et al., 2010). Another small randomized crossover study with 38 women showed no effect (Budeiri et al., 1996).

B. Urinary Tract Infections

Urinary tract infections (UTIs) are one of the most common bacterial infections in women, and women are 30 times more likely to develop UTIs compared with men (Little et al., 2010). The bacterium *Escherichia coli* is mainly responsible for most uncomplicated UTIs. Botanicals traditionally used to treat UTIs are reviewed below.

1. Vaccinium macrocarpon (Cranberry). Cranberry, which is the second most popular botanical sold in the US (Table 1), has a well-recognized medicinal use primarily in preventing UTIs (Yarnell, 2002; Rossi et al., 2010). The mechanism is generally thought to involve inhibition of adhesion of P-fimbriated (proteinaceous appendages) *E. coli* that firmly attach to uroepithelial cells by the type A proanthocyanidins in cranberry juice (Fig. 18) (Foo et al., 2000; Guay, 2009; Vasileiou et al., 2013). Three species of cranberry (*V. macrocarpon, V. oxyccocus, V. vitis-idaea*) have different amounts and types of proanthocyanidins, which may explain the variable clinical data and further emphasizes the need for full chemical and biological standardization of cranberry extracts (Davidson et al., 2014). The Cochrane Collaboration previously recommended cranberry products for the prevention of UTIs in young and middle-aged women; however, questions of efficacy remain because of the heterogeneity in the clinical trial design and the lack of consensus on dosage, formulation, and time of use (Jepson et al., 2012). The most recent update suggests that cranberry juice is less effective than previously indicated, and they do not currently recommend cranberry juice for the prevention of UTIs. In addition, other cranberry preparations such as powders need to be fully standardized both chemically and biologically to the active compounds to ensure potency before being evaluated in clinical studies or recommended for use. The existing clinical trials suggest that cranberry is more effective at preventing rather than treating UTIs (Vasileiou et al., 2013); however, it is quite possible that the studies with *V. macrocarpon* in particular were under-dosed in the bioactive proanthocyanidins and placebo-controlled clinical trials that use standardized cranberry products are needed to establish efficacy (Davidson et al., 2014).

2. Arctostaphylos uva-ursi (Bearberry). Bearberry is a North American shrub, the leaves of which have ethnobotanical use for treating lower urinary tract infections (Yarnell, 2002). Bearberry contains tannins, which have astringent effects and can help to shrink and tighten mucous membranes, reducing inflammation and fighting infection. The antimicrobial compound could be arbutin, which is hydrolyzed in the gut to produce glucose and hydroquinone that can be further oxidized to para-quinone (Fig. 19) (de Arriba et al., 2013). Because hydroquinone/quinone is carcinogenic and tannins can cause nausea and
vomiting, low doses of bearberry (800 mg arbutin/day) are recommended for less than 1 week at a time. Currently there are no clinical trials on bearberry leaf alone to support the efficacy claims for treating UTIs.

III. Botanicals Used during Pregnancy/Lactation

A. Nausea

Nausea and vomiting during pregnancy can severely impact quality of life as well as pose significant health risks for some women. Botanicals traditionally used to relieve nausea associated with morning sickness are reviewed below.

1. *Zingiber officinale* (Ginger). Ginger might be an effective treatment of nausea associated with pregnancy, although the clinical data have been mixed (Kennedy et al., 2013; Giacosa et al., 2015; Marx et al., 2015). In general, ginger extracts have been shown to accelerate gastric emptying (promotility, prokinetic) and stimulate gastric antral contractions (Micklefield et al., 1999; Wu et al., 2008b). In addition, four randomized controlled clinical trials on the use of ginger for pregnancy-induced nausea and vomiting showed that orally administered ginger was significantly more effective than placebo at reducing frequency and intensity of nausea (Ding et al., 2013). The current literature suggests that ginger is safe in pregnant women; however, it is still not clear what the dose and length of treatment should be as well as the potential for drug/botanical interactions. GraviFrisk Ferrosan A/S (Søborg, Denmark), which contained a daily dose of 6 g dried ground ginger, was withdrawn from the Danish market in February 2008 because of inadequate scientific documentation of safety (Jacobsgaard, 2008). It is believed that the active compounds responsible for these biological effects are gingerols and shogaols (Fig. 15), which are cholinergic M3 and serotonergic 5-HT3 receptor antagonists (Abdel-Aziz et al., 2006; Pertz et al., 2011). Gingerols, shogaols, and zingerone are metabolically unstable and are readily oxidized to phenoxy radicals and potentially quinones or quinone methides (Fig. 15), which could play a role in their chemopreventive activities (Gan et al., 2013; Mason and Thompson, 2014). The instability of these compounds could explain some of the varied activities reported in clinical trials. In general, the popular use of ginger for the relief of nausea during pregnancy is substantiated by a number of clinical trials that generally report efficacy relative to placebo and little toxicity (Dante et al., 2014). Similar results have been reported for ginger clinical trials for chemotherapy-induced nausea, motion sickness, and postoperative nausea (Dante et al., 2014).

B. Lactation

The most common reported reason for stopping breast feeding is the perception of inadequate milk production. A number of women have turned to herbal galactagogues to stimulate milk production despite the lack of documented efficacy and safety (Mortel and Mehta, 2013; Amer et al., 2015). Botanicals traditionally used to treat lactation disorders are reviewed below.

1. *Trigonella foenum-graecum* (Fenugreek). Fenugreek, which is a seed spice used to enhance flavor, color, and texture of food, also has several medicinal
properties including galactagogue (lactation inducer) effects (Yadav and Baquer, 2014). It is the most commonly used herbal galactagogue, although there is conflicting reports of its efficacy (Mortel and Mehta, 2013). Fenugreek is thought to stimulate sweat production and because the breast is a modified sweat gland, it may stimulate breast milk production through this mechanism (Gabay, 2002). It has also been reported that fenugreek contains diosgenin (Fig. 20), which could modify the endocrine system enhancing milk production (Sreeja et al., 2010). Sugars of the flavonoids apigenin (Fig. 13) and luteolin (Fig. 20) have also been reported. In a well-designed clinical trial of 66 mother-infant pairs randomly assigned to three groups; fenugreek tea, apple tea, and control, maximum weight loss was significantly lower in the infants and milk volume was higher in the mothers receiving fenugreek tea (Turkyilmaz et al., 2011). The research on the health benefits of fenugreek including its use as a galactagogue and its lack of side effects suggest potential as a dietary supplement (Yadav and Baquer, 2014).

2. Silybum marianum (Milk Thistle). The most common use of milk thistle supplements is for liver detoxification (Greenlee et al., 2007). Galactagogue activity of milk thistle has also been reported and its use is increasing (Forinash et al., 2012; Zapantis et al., 2012). It has been described in an in vivo study that milk thistle and specifically, silymarin (Fig. 21), a mixture of flavonolignans and some precursor flavonoids contained in milk thistle, increased prolactin levels in female rats and that this might lead to a galactagogue effect (Forinash et al., 2012). In an in vivo study with gestational pigs, feeding of 4 g silymarin twice daily for 20 days resulted in significant increase of circulating prolactin levels (Farmer et al., 2014). In addition, some parameters of mammary gland development changed through silymarin treatment; however, the increase in prolactin was not sufficient to have beneficial effects on mammary gland development in late gestation. The influence of silymarin on the amount of milk formation was not analyzed in this study. One placebo-controlled clinical trial analyzed silymarin’s effectiveness as galactagogue in women (Forinash et al., 2012). Although an increase in milk formation was observed in this small clinical trial, this study had several limitations, which warrants further examination of milk thistle as a galactagogue in larger clinical investigations. The estrogenic activity of milk thistle and of silymarin was analyzed in different studies with varying results. Some studies describe weak estrogenic activities for silymarin and especially for its major flavonolignan, silybin B, and for quercetin and taxifolin (Pliskova et al., 2005) (Fig. 21). One 12-week in vivo study showed that silymarin exerted estrogenic effects, such as increase of uterine weight and reduction of bone loss in ovariectomized rats (El-Shitany et al., 2010). A 1-week in vivo study using a lower dose of silymarin also showed an influence on osteoblast parameters but did not observe a uterotrophic effect for silymarin (Seidlova-Wuttke et al., 2003). Silymarin is reported to mainly exert estrogenic activity through the ERβ receptor (Seidlova-Wuttke et al., 2003); however, it is controversial whether silibin B (El-Shitany et al., 2010) or other compounds contained in silymarin, such as taxifolin and quercetin, are responsible for the described ERβ-selective effect (Powers and Setzer, 2015).
In general, the safety and efficacy of milk thistle as a galactagogue has not been analyzed in detail and further studies are warranted.

IV. Botanicals Used by Menopausal Women

A. Menopausal Symptoms

The decrease in estrogen production at menopause leads to life-altering symptoms such as hot flashes and night sweats, cognitive instability, sleep disturbances, and vaginal atrophy (Nelson, 2008). These symptoms can be effectively managed by hormone therapy; however, as mentioned above, the results of the women’s health initiative have led many women to complementary or alternative remedies such as the botanical dietary supplements (Table 1) (Borrelli and Ernst, 2010; Depypere and Comhaire, 2014; Poluzzi et al., 2014; Taylor, 2015). Botanicals traditionally used to treat menopausal symptoms are reviewed below.

1. Serotonergic Mechanism. Estrogen withdrawal during menopause results in a decline in the release of neurotransmitters, primarily norepinephrine and serotonin (5-hydroxytryptamine; 5-HT), leading to a change in thermoregulation in the hypothalamus (Shanafelt et al., 2002) resulting in hot flashes and night sweats. Increase in the amount of serotonin and activating certain 5-HT receptors as well as inhibition of serotonin reuptake in synapses through blocking of serotonin transporters with prescription antidepressant SSRIs are viable approaches in preventing hot flashes (Fig. 22). However, there are also a number of undesirable outcomes such as nausea, sexual dysfunction, weight gain, and sleep disturbances associated with these remedies that have led women to consider natural botanicals with potential serotonergic efficacy (Nachtigall, 2010; Kintscher, 2012; Hajirahimkhan et al., 2013a).

a. Actaea/Cimicifuga racemosa (black cohosh). Black cohosh is the most popular botanical for menopausal symptom relief in the United States (Taylor, 2012, 2015) (Table 1, rank number 4). The roots and rhizomes of black cohosh have been used by Native Americans for a variety of women’s health issues for centuries. It is generally agreed that black cohosh is not estrogenic and the mechanism of action may involve modulation of the serotonergic system similar to the effects of antidepressants (Winterhoff et al., 2003; Borrelli and Ernst, 2008; Powell et al., 2008; Hajirahimkhan et al., 2013a; Wuttke et al., 2014). The active compounds in black cohosh are not known, although \textit{N}-methylserotonin has been identified as a potential serotonin receptor agonist (Fig. 9) (Powell et al., 2008). The efficacy reports from black cohosh clinical trials have been highly variable (Shams et al., 2010). A meta-analysis of randomized placebo-controlled clinical trials concluded that of the six trials that demonstrated a significant improvement in the black cohosh group compared with placebo, a 26% improvement was calculated (95% confidence interval, 11–40%) (Shams et al., 2010). For example, Ruhlen et al. (2007) observed reduction of hot flashes in women taking a black cohosh extract containing 2.5% triterpenes for 12 weeks. The effect returned to baseline after a 12-week washout period. The extract did not have any effect on serum estrogenic markers, trefoil factor 1 gene expression levels and cellular morphology in the women’s nipple aspirate fluids, demonstrating no detectable estrogenic effect on the breast tissue (Ruhlen et al., 2007). More recent clinical trials have reported negative effects for black cohosh with no significant difference from placebo for relief of hot flashes. A black cohosh extract of 40 mg/day was not superior to placebo for menopausal symptoms or improving quality of life scores in Thai women (Tanmahasamut et al., 2015). Similarly, a standardized extract of 125 mg/day for 1 year also was not as effective as placebo (Geller et al., 2009). Given the popularity of black cohosh for relief of menopausal symptoms, larger placebo-controlled clinical trials are needed with fully standardized extracts before questions of efficacy and safety can be answered.

b. Valeriana officinalis (valerian). Extracts of valerian roots are widely used for inducing sleep and improving sleep quality, suggesting they might be effective for menopausal symptoms especially night sweats (Bent et al., 2006). Serotonergic activity has also been reported for valerian extracts, and valerenic acid has been identified as a potential partial agonist of the 5-HT$_{5A}$ (Fig. 16) (Dietz et al., 2005b). In a double-blind placebo-controlled clinical trial, 68 women receiving 255 mg valerian capsules three times daily for 8 weeks showed a significant reduction in hot flash frequency and intensity (Mirabi and Mojab, 2013). Another randomized placebo-controlled trial with a mixture of valerian...
and lemon balm (100 women, 50–60 years, 160 mg/day valerian) showed a significant reduction in sleep disorders with the treated group (Taaavoni et al., 2013). A recent 8-week study on 60 postmenopausal women (45–60 years old) showed a significant improvement in menopausal symptoms in women receiving 530 mg of valerian root capsules twice a day (Izadjoo et al., 2015). No adverse effects were reported in these trials, suggesting valerian supplements at these doses are safe.

2. Estrogenic Mechanism. Botanicals with estrogenic activity can mimic the effects of endogenous estrogens lost during menopause (Hajirahimkhan et al., 2013a). Estrogens often activate biological responses through binding to estrogen receptors (ERs) including ER\( \alpha \) and ER\( \beta \), followed by dimerization of ERs and interaction with estrogen responsive elements (EREs) at the promoter of the estrogen responsive genes, thus activating transcription and generating estrogenic effects that are crucial for normal physiological functions (Fig. 23) (Nilsson et al., 2001; Bjornstrom and Sjoberg, 2005; Ellmann et al., 2009; Jia et al., 2015). It is believed that ER\( \alpha \) induction is associated with the proliferative effects of estrogens, whereas ER\( \beta \) opposes the ER\( \alpha \)-dependent proliferation (Deroo and Buensuceso, 2010; Shanle and Xu, 2010; Thomas and Gustafsson, 2011; Jia et al., 2015). Botanicals with estrogenic effects, particularly the ones with ER\( \beta \) selectivity, may offer safer alternatives to conventional prescription HT regimens.

a. Isoflavones.

i. Glycine max (Soy). Soy is one of the major sources of protein in Asian diets in particular (Low Dog, 2005; Taylor, 2015). Isoflavones in soy foods are mainly present as glycosides (i.e., genistin, daidzin), which are hydrolyzed by \( \beta \)-glucosidases in the intestine forming the estrogenic ER\( \beta \)-selective aglycones, genistein and daidzein (Fig. 24) (Lin and Giusti, 2005; Lopez-Gutierrez et al., 2014; Taylor, 2015). It has also been reported that daidzein metabolism by the intestinal microflora results in the formation of \( S \)-equol, which has better estrogenic activity and a higher affinity for ER\( \beta \) than daidzein (Setchell et al., 2005; Jiang et al., 2013) (Fig. 24). Different anaerobic bacteria can reduce daidzein to \( S \)-equol through three different reductase enzymes and one dihydrodaidzein racemase (Shimada et al., 2011; Lee et al., 2016). Genetic polymorphism in equol production has been demonstrated, which in part may explain the variability in relieving menopausal symptoms (Hong et al., 2012).

Most clinical trials have used dosages ranging from 50 to 100 mg/day isoflavones (Low Dog, 2005). The
North American Menopause Society has concluded that soy-based isoflavones are modestly effective in relieving menopausal symptoms (North American Menopause Society, 2011). A meta-analysis of the use of soy dietary supplements for hot flashes showed a statistically significant decrease in hot flashes, although the clinical efficacy is questionable (Bolanos et al., 2010). A review published by the Cochrane Collaborative on 43 randomized controlled trials concluded that there was no conclusive evidence that soy supplements reduced menopausal hot flashes (Lethaby et al., 2013). Fortunately, no estrogenic effects on the endometrium or vagina were reported in these studies with up to 2 years of use. The poor bioavailability of genistein and daidzein from soy may explain the variable and relatively modest if any effects on menopausal symptoms (Yang et al., 2012; Rodriguez-Morato et al., 2015).

**ii. Trifolium pratense (Red Clover).** Unlike soy, the major isoflavones in red clover are the proestrogens biochanin A and formononetin (Fig. 24) (Booth et al., 2006). These methoxy precursors are demethylated by cytochrome P450 isozymes in the intestine and liver to the estrogenic ERβ-selective genistein and daidzein, respectively (Tolleson et al., 2002). These data suggest that red clover isoflavones might have higher bioavailability compared with soy and could explain why the red clover clinical trials tend to show more efficacy for menopausal symptoms compared with those evaluating soy products (Piersen et al., 2004; Thomas et al., 2014). A meta-analysis of four clinical trials using the red clover extract marketed as Promensil (Novogen Ltd, Hornsy, Australia) showed a slight but statistically significant reduction in hot flashes (Lethaby et al., 2013). In addition, there was no increase in endometrial thickness or breast density, suggesting a lack of estrogenic activity in hormone-sensitive tissues. A recent trial of 72 women randomly divided between placebo and 40 mg dried red clover daily for 12 weeks showed a significant reduction in menopausal symptoms as measured by the menopause rating scale (Shakeri et al., 2015). Other clinical trials have not shown a significant difference from placebo, particularly for hot flash relief (Geller et al., 2009; Hall et al., 2011).

**iii. Pueraria lobata (Kudzu).** Kudzu is used in traditional Chinese medicine for the treatment of menopausal symptoms (Hajirahimkhan et al., 2013a). The major isoflavone in kudzu is puerarin, which is the C8-glucoside of daidzein (Guerra et al., 2000; Delmonte et al., 2006) (Fig. 24). Puerarin is metabolized to daidzein by intestinal bacteria (Park et al., 2006; Nakamura et al., 2011). The same isoflavonoids found in red clover and soy are also found in kudzu in lower amounts (Delmonte et al., 2006; Zhang et al., 2009). A randomized controlled clinical trial (127 women, 50–65 years old, 3 months) receiving kudzu standardized to 100 mg isoflavones, HT, or no treatment showed no significant changes compared with control (Woo et al., 2003; Ulbricht et al., 2015).
iv. Eriosema laurentii (Guinea-Bissau).
Guinea-bissau is a botanical found in Cameroon traditionally used for infertility and menopausal symptoms (Ntie-Kang et al., 2013). Phytoestrogens isolated from guinea-bissau include ERα-selective lupinalbin A (Fig. 25) and ERβ-selective genistein (Fig. 24) (Ateba et al., 2014). No clinical trials have been reported on the use of guinea-bissau for menopausal symptoms.

b. Humulus lupulus (hops).
The strobiles of hops are often added to beer to produce bitter, tart, hoppy flavors. Hop extracts are also a popular botanical for sleep-inducing effects, especially in Europe (Blumenthal and German Federal Institute for Drugs and Medical Devices Commission, 2000; Zanoli and Zavatti, 2008; Salter and Brownie, 2010). Hop extracts are also present in some dietary supplements for managing menopausal symptoms (Taylor, 2012). The most potent phytoestrogen in hops is the ERα-selective agonist 8-prenylnaringenin (8-PN), which is in part formed from the chemopreventive isoflavone xanthohumol through cyclization and P450 catalyzed demethylation as shown in Fig. 26 as well as through metabolism of isoxanthohumol by microbiota (Nikolic et al., 2005; Chadwick et al., 2006; Possemiers et al., 2006). A few clinical trials have been published evaluating the efficacy of hops extracts on menopausal symptoms (Taylor, 2015). A randomized placebo controlled trial with 67 menopausal women over 12 weeks receiving hops extract standardized to 100 or 250 mg 8-PN or placebo showed significant effects at 6 weeks for the lower dose. However, no effect was observed at higher doses, and the lower dose was not significantly different from placebo after 12 weeks as measured by the Kupperman index and quality of life questionnaire (Heyerick et al., 2006). The authors noted the relatively low effective dose of ERα-selective 8-PN, which is 100-fold more potent than the ERβ-selective isoflavones genistein and daidzein (Milligan et al., 1999; Overk et al., 2008). However, given the potent ERα agonistic activity of 8-PN in hops extracts, safety with respect to the effect on the endometrium and other hormone sensitive tissues needs further study. In a smaller study (randomized, double-blind, placebo-controlled, crossover study, 36 menopausal women), women receiving either placebo or hops extract standardized to 8-PN for 8 weeks and then switching treatments for 8 weeks showed weak efficacy of the extract over placebo when the extract was taken after the placebo treatment until week 16 (Erkkola et al., 2010). However, these results might not be robust, considering the small sample size and large number of variables included in the extensive statistical analysis (Taylor, 2015). A more recent trial using a daily dose of 500 mg hops in tablet form versus placebo (120 women, 90 days) showed a statistically significant reduction in menopausal symptoms and a dramatic reduction in hot flashes (Aghamiri et al., 2016). However, there are several problems with this trial including, the lack of standardization of the extract, the recruitment of women from multiple sites, and the lack of a placebo effect. No adverse effects were reported in any of these trials. More clinical trials are needed before the safety and efficacy of hops extracts for menopausal symptom relief can be established.

c. Glycyrrhiza species (licorice).
Licorice is a widely used plant, mainly as a sweetening agent in tobacco, in food and beverages, and in toothpastes. It consists of more
than 30 species, from which a few have been studied for several biological effects (Asl and Hosseinzadeh, 2008; Hajirahimkhan et al., 2013b). Licorice is commonly present in menopausal botanical supplements in the United States (Taylor, 2012). There are three pharmacoepial licorice species, *Glycyrrhiza uralensis*, *G. glabra*, and *G. inflata*; however, the specific species used is often not identified or mislabeled in supplements. The estrogenic activities of different licorice species are variable and likely depend on the type and amounts of bioactive compounds, emphasizing the importance of fully standardizing extracts using chemical, genetic, and biological methods (Liu et al., 2001; Hajirahimkhan et al., 2013a). After evaluating a large number of licorice samples that were local to certain regions of the world Kondo et al. (2007a) reported that *G. uralensis* and *G. glabra* had the highest and the lowest amounts of the phytoestrogen liquiritigenin (Fig. 27), respectively. Liquiritigenin was reported to be a selective ERβ agonist in the ER binding assay and in ERβ-ERE-luciferase activity assay in U2OS cells (Mersereau et al., 2008). In vivo liquiritigenin did not enhance proliferation of MCF-7 (ERα+) xenograft or induce uterine weight in nude mice, suggesting liquiritigenin is unlikely to affect hormone sensitive tissues (Mersereau et al., 2008). Isoliquiritigenin, the precursor chalcone of liquiritigenin was also shown to exhibit estrogenic effects (Fig. 27) (Maggiolini et al., 2002). However, the conversion of isoliquiritigenin to liquiritigenin could play a significant role in exerting the observed activity (Hajirahimkhan et al., 2013b). There have been very few clinical studies evaluating licorice for the treatment of menopausal symptoms. In a double-blind placebo-controlled trial, a significant drop in hot flashes was reported with 90 women receiving licorice 330 mg/day or placebo for 8 weeks (Nahidi et al., 2012). However, no mention about the species of licorice extract was available and no placebo effect was observed. Another recent trial with six women compared the efficacy of licorice extracts (1140 mg/day)
for 90 days with traditional HT for hot flash relief claiming similar efficacy (Menati et al., 2014). Both trials have significant problems ranging from small size, lack of extract standardization, self-reporting surveys, lack of placebo group, and lack of placebo effect, which can be as high as 50% in menopause trials. More in-depth studies are needed to define the efficacy and safety of licorice for menopausal symptoms.

d. Rheum rhaponticum (rhubarb). Rhubarb is also a common herb for menopausal symptom relief, particularly in Germany (Vollmer et al., 2010; Taylor, 2012; 2015). A special extract prepared from the roots of Rheum rhaponticum called ERr731 [marketed under the trade name Phytoestrol N (Mueller Goeppingen, Goeppingen, Germany)] has been in use in Germany for decades without any significant side effects such as endometrial hyperplasia, spotting, or breakthrough bleeding (Werber et al., 2007). This extract mainly consists of rhaponticin and desoxyrhaponticin, which are converted to the resveratrol-like aglycones rhapontigenin and desoxyrhapontigenin by the microbiome and glycosylases (Fig. 28) (Kim et al., 2000; Werber et al., 2007). Weak ERβ activity has been measured for both the extract and the aglycones rhapontigenin and desoxyrhapontigenin in transfected HEC-1B adenocarcinoma cells and U2OS cells (Moller et al., 2007; Werber et al., 2007). Rhapontigenin is more active than desoxyrhapontigenin and it is tempting to suggest that P450-catalyzed O-demethylation giving the resveratrol catechol piceatannol might be responsible for the estrogenic activity (Werber et al., 2007). It has been shown that piceatannol binds estrogen receptors and stimulates the growth of estrogen-dependent cancer cells (Piotrowska et al., 2012). The efficacy and safety of ERr731 for menopausal symptoms has been studied in a number of double-blind placebo-controlled trials with positive results (Heger et al., 2006; Kaszkin-Bettag et al., 2008; Hasper et al., 2009). All these trials show that the rhubarb extract was well tolerated both for short duration (12 weeks) as well as long term (up to 2 years), successfully decreased the Menopause Rating Scale, and increased quality of life.

e. Vitex agnus-castus (chasteberry). Chasteberry is also a popular botanical added to botanical supplements for menopause (van Die et al., 2009; Taylor, 2012). It was shown to have a weak binding affinity for ERs and no estrogen-sensitive alkaline phosphatase induction in Ishikawa cells; however, it did induce the estrogen-sensitive gene PgR (progesterone receptor gene) mRNA in this cell line (Liu et al., 2001). Linoleic acid (Fig. 13) was isolated as the “active” estrogenic constituent of chasteberry based on bioassay guided fractionation of the crude extract using the ER binding assay (Liu et al., 2004). However, linoleic acid is a fatty acid and could form nonspecific binding to ERs and progesterone receptor proteins, leading to false-positive results. Moreover, induction of PgR could be related to possible progestogenic activity of the extract and not necessarily its ERα-dependent effects. It was shown that four different species of chasteberry enhance MCF-7 cell proliferation (Hu et al., 2007b). In addition, the essential oils of Vitex rotundifolia, which is mainly composed of linoleic acid, strongly enhanced MCF-7 cell proliferation, and the effect could be blocked by the pure antiestrogen, ICI 182,780 (7α,17β-9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estr-1,3,5(10)-triene-3,
17-diol) (Hu et al., 2007a). Similarly, Ibrahim et al. (2008) reported that an ethanolic extract of chasteberry enhanced uterine weight in Sprague-Dawley rats. These data suggest that chasteberry extracts have ERα-dependent estrogenic activity. It was also shown that chasteberry extract selectively bound ERβ and bioassay guided fractionation of the crude extract resulted in the isolation of the weak ERβ ligand apigenin (Fig. 13) (Jarry et al., 2003). The ERβ selectivity of apigenin was also shown in competitive binding assays in addition to general estrogenic activity in a yeast based and MCF-7 cell growth assays (Choi et al., 2008). Despite the popularity of chasteberry with herbalists and its use as a component of menopausal formulations with other botanicals, there are no clinical trials with chasteberry as a sole agent for the relief of menopausal symptoms (van Die et al., 2009). However, the studies with combinations of botanicals including chasteberry are promising, suggesting further investigation of *Vitex agnus-castus* for menopausal symptom relief (van Die et al., 2009).

*f.* Linum usitatissimum (flaxseed). Flaxseed is a major source of lignans that are metabolized by the intestinal flora into the weakly active phytoestrogens enterolactone and enterodiol (Fig. 29) (Dew and Williamson, 2013). Lignans reside in cell walls and are not bioavailable without crushing, and as a result the best sources for women are flaxseed flour and flaxseed meal. Flaxseed oil is a good source of α-linolenic acid but does not contain lignans (Taylor, 2015). In a randomized placebo-controlled clinical trial (90 women, 1 g/day flaxseed extract), modest but significant effects were observed in self-reporting relief of menopausal symptoms (Colli et al., 2012). No adverse effects related to flaxseed treatment were reported. A meta-analysis of recent randomized clinical trials examining the efficacy of flaxseed for menopausal symptom relief concluded that there is little evidence to support the use of this dietary supplement for menopause or for bone health (Dew and Williamson, 2013).

g. *Epimedium* species (horny goat weed). Horny goat weed originating from different *Epimedium* species has been used in traditional Chinese medicine for over 2000 years to enhance libido in men and women as well as for symptoms of menopause and PMS (Ma et al., 2011). The flavonoid icarin can be metabolized to icaritin and desmethylicaritin, which is likely responsible for the mostly ERα-selective estrogenic bioactivities (Fig. 30) (Wang and Lou, 2004; Cao et al., 2012; Xiao et al., 2014). These prenylated flavonoids are structurally similar to the potent ERα estrogen 8-PN in hops (Fig. 26, see above). One clinical trial showed that an extract of horny goat weed could increase estrogen levels and improve lipid profiles in postmenopausal women without any significant side effects (Yan et al., 2008). No clinical trials using horny goat weed for menopausal symptoms have been reported.

*h.* Lepidium meyenii (maca). Maca has been used in South America for centuries for infertility and female

---

**Fig. 28.** Phytochemicals in rhubarb and their metabolites.

**Fig. 29.** Phytochemicals in flaxseed.
hormone balance, especially for menopausal symptoms (Lee et al., 2011b; Gonzales, 2012; Taylor, 2015). Maca extracts have been shown to have estrogenic activity by increasing MCF-7 cell proliferation (Valentova et al., 2006), although the active phytoestrogens are not known. Maca extracts contain a number of phytosterols including beta-sitosterol and campesterol (Fig. 31) as well as free fatty acids including linolenic acid (Fig. 17) (Dini et al., 1994). A systematic review of clinical trials concluded that there was limited evidence for the effectiveness of maca for relief of menopausal symptoms; however, the sample size, the number of trials, and the quality of the trials were too limited to establish firm conclusions on efficacy and safety (Lee et al., 2011b).

i. Oenothera biennis (evening primrose). Evening primrose oil is a good source of omega-6 essential fatty acids including \( \gamma \)-linolenic acid (Fig. 17). In a randomized placebo-controlled clinical trial (56 menopausal women), a significant improvement in the severity of menopausal hot flashes was reported in the evening primrose (500 mg/day, 6 weeks) group (Farzaneh et al., 2013). A systematic review of evening primrose oil for menopausal symptoms suggests that although the herb is well tolerated, efficacy is not clinically significant (Bayles and Usatine, 2009).

j. Medicago sativa (alfalfa). Alfalfa is another botanical that is a good source of isoflavones. The coumestan derivative coumestrol (Fig. 32) is the major estrogenic phytochemical, although the licorice flavonoids liquiritigenin and isoliquirtigenin have also been detected (Fig. 27) (Hong et al., 2011). No clinical trials for menopause using alfalfa alone have been reported.

3. Unknown Mechanism.

a. Dioscorea villosa (wild yam). Wild yam contains diosgenin, which is used in the manufacturing of synthetic steroids (Taylor, 2015). Diosgenin can be chemically converted to progesterone, although there is no biological pathway for the conversion in vivo (Fig. 20). When given as a cream, there was no significant effect on menopausal symptoms in 23 women after 3 months compared with placebo (Komesaroff et al., 2001). No significant adverse effects were reported. The current recommendations are that yam creams are ineffective for menopause and because many contain adulterants they should be avoided (Taylor, 2015).

b. Angelica sinensis (dong quai). The roots of Angelica sinensis have been used for restoring female hormonal balance in traditional Chinese medicine for centuries (Hook, 2014). The estrogenic activity of dong quai is controversial (Liu et al., 2001; Lau et al., 2005; Circosta et al., 2006). For example, it was shown that dong quai had proliferative effects in MCF-7 (ER\( \alpha \)+) cells, whereas it did not induce ER\( \alpha \)/ER\( \beta \)-dependent luciferase transcription in transfected HeLa cells and did not show uterotrophic activity in CD-1 mice (Amato et al., 2002). However, enhanced uterine weight, change in vaginal cytology, and reduced luteinizing hormone levels in female Wistar rats treated with an ethanolic extract of dong quai have been shown (Circosta et al., 2006). Similarly, cell-based studies showed controversial results. Dong quai methanolic extracts did not show binding affinity to ERs, induce alkaline phosphatase activity in Ishikawa cells, or induce transcription of estrogen responsive genes (Liu et al., 2001). Moreover, an ethanolic extract of dong quai did not exhibit estrogenic activity in a yeast-based assay over the concentration range of 0.1–1000 \( \mu \)g/ml (Zhang et al., 2005). It has been shown that the lipophilic fraction of a methanolic extract (rich in ligustilide, Fig. 10) of dong quai at 20 \( \mu \)g/ml significantly inhibited alkaline phosphatase induction in the presence of estradiol in Ishikawa cells, suggesting an antiestrogenic potential (Godecke et al., 2012). To date, there have not been any reports of a purified compound, which could be responsible for the observed estrogenic/antiestrogenic activities of dong quai. These studies suggest that further research with well-defined extracts are needed to delineate the estrogenic/ antiestrogenic potential of dong quai as well as the active compound. One reason for the contradictory results regarding the estrogenic activities of dong quai could be associated with the instability of its phthalide fractions, in particular Z-ligustilide as discussed previously (Schinkovitz et al., 2007). In traditional Chinese medicine, dong quai is usually combined with other botanicals; therefore very few clinical trials on dong quai alone have been reported. One study with 71 postmenopausal women randomized to 4.5 g dong quai/day or placebo

![Fig. 30. Phytochemicals in horny goat weed.](image-url)
for 24 weeks showed no effect on menopausal symptoms (Hirata et al., 1997). No estrogenic effects on the endometrium or vagina were observed and no significant side effects were reported in this trial. Conclusive data on the relative efficacy of dong quai for menopausal symptoms are currently unavailable.

B. Osteoporosis

A consequence of low estrogen levels at menopause is an increase in osteoporosis risk. Botanicals, which may protect against osteoporosis, are reviewed below. In general, there is insufficient evidence to make recommendations on the effect of botanicals on bone health.

1. Isoflavones. Because most isoflavones are ERβ-selective ligands, it should be possible to exploit this selectivity and target mainly bone cells without adversely affecting hormone-sensitive tissues such as the uterus and the breast. Genistein (Fig. 24) has been shown to stimulate bone formation, inhibit bone resorption, and prevent bone loss in ovariectomized rat models (Taylor et al., 2009; Fu et al., 2014). It has been demonstrated in a few randomized, double-blind placebo-controlled studies that genistein (54 mg/day for 1 or 2 years) was effective in preventing bone loss in postmenopausal women (Morabito et al., 2002; Marini et al., 2007). Favorable effects have been demonstrated in other clinical studies measuring bone mass density and bone turnover markers; however, the long-term effects on prevention of fractures have not been established (Lagari and Levis, 2014; Poluzzi et al., 2014). The data suggest that diets rich in isoflavones are beneficial for bone health in the long term, although the magnitude of the effects and the exact mechanism of how isoflavones could protect bones have not been determined. There is also evidence to suggest that the positive effects of isoflavones on bone health could vary as a function of age. Isoflavones could be more effective in younger women before loss of estrogen receptors observed in postmenopause (Reinwald and Weaver, 2006). Most clinical trials with soy proteins and enriched soy isoflavones were not effective in decreasing bone loss, in particular at common fracture sites in healthy perimenopausal and postmenopausal Western women (Alekel et al., 2010). Different studies have also analyzed red clover products for prevention of osteoporosis. A patented aqueous and fermented red clover extract standardized to 37.1 mg isoflavones per day or a placebo solution were administered to women suffering from menopausal symptoms in a 3-month, randomized, double-blind and parallel designed trial (Thorup et al., 2015). A significant decline in the bone mineral density of the lumbar spine (lower back) in the placebo group but not in the red clover group was observed, suggesting a positive effect on bone health by the red clover extract. However, it has to be noted that the actual changes were small and that the differences could also be due to the variability in bone density scanning. Studies with bisphosphonate therapy showed that reliable treatment effects can be best observed after 3 years, because the within-person variations differ widely with dual-energy X-ray absorptiometry measurement (Sharma and Stevermer, 2009). Therefore, longer clinical studies with red clover would be necessary to evaluate the efficacy as a treatment of osteoporosis. Until more rigorous clinical trials are completed, soy foods and/or soy or red clover supplements cannot be recommended as alternatives for antiosteoporotic medications (Messina et al., 2004; Nieves, 2013; Poluzzi et al., 2014).

2. Others. The evidence supporting the use of other botanicals for prevention of osteoporosis is very limited. Maca prevents bone loss in rat models of estrogen-deficient bone loss (Zhang et al., 2006). Wild yam and fenugreek have effects on bone mineral density in ovariectomized rats (Chiang et al., 2011; Folwarczna et al., 2014). Silymarin has also been studied as remedy against osteoporosis in animal models (Milic et al., 2013). Horny goat weed has a long history in treating osteoporosis in traditional Chinese medicine, which was recently reviewed (Ma et al., 2011; Indran et al., 2016).

V. Botanicals for Breast Cancer Prevention

Many botanicals that are used for women’s health are likely to have additional health beneficial effects, including antioxidant, antimicrobial, anti-inflammatory, and chemopreventive activities (Rice-Evans, 2001; Rahman et al., 2006). Although describing all these effects is beyond the scope of this review, the prevention of estrogen-dependent cancers, especially breast cancer, is summarized below for some representative women’s health botanicals (Snelten et al., 2012; Dietz and Bolton, 2013; Cojocneanu Petric et al., 2015). Breast cancer prevention is especially important for postmenopausal women, because breast cancer risk increases with age and therefore postmenopausal women have a higher risk than premenopausal...
women (Wang et al., 2015b). Breast cancer is the most frequent cancer occurring in women, and it is estimated that 246,660 women will be diagnosed with breast cancer in the US in 2016 (Siegel et al., 2016). For years, researchers have studied the causes of this disease and have found a pivotal role for estrogens in the development of breast cancer (Huang et al., 2015; Ziegler et al., 2015). Four major mechanisms contribute to the overall development of estrogen-dependent cancers including hormonal, chemical, inflammatory, and epigenetic (Fig. 33).

A. Hormonal Pathway

Estrogens bind to the estrogen receptor (ER), increasing cell proliferation which leads to an enhanced risk of mutations (Fig. 23) (Santen et al., 2015). These complex processes involve genomic and nongenomic ER signaling (Bjornstrom and Sjoberg, 2005). For this review, the emphasis will be put on direct binding of phytoestrogens or estrogens to the two major estrogen receptors that are found in the normal breast tissue, ERα and ERβ (Huang et al., 2015), and their binding to the ER (Fig. 23). Although the exact roles of the two ERs are still under intensive investigations, it has been shown that ERα leads to proliferation of breast cells and that ERβ represses proliferation and is proapoptotic (Huang et al., 2015). In postmenopausal women, estradiol is produced locally by aromatization of androgens in extragonadal sites, such as breast adipose tissue, leading to enhanced local estrogen concentrations that can lead to increased proliferation of epithelial cells (Wang et al., 2015b) (Fig. 23). Modulation of aromatase activity and thus estrogen levels is another way through which phytochemicals are able to influence the hormonal estrogen pathway.

B. Chemical Pathway

The second estrogen carcinogenesis pathway involves estrogen metabolism by P450 to catechols, which are oxidized to genotoxic o-quinones (Fig. 34) (Bolton, 2011; Snelten et al., 2012; Yager, 2015). P450 1A1 and 1B1, which metabolize the 2- and 4-hydroxylation pathways, respectively, are regulated by the arylhydrocarbon receptor (AhR), which binds to the xenobiotic response element (XRE) in the nucleus (Murray et al., 2014). These P450s are also responsible for the bioactivation of polycyclic aromatic hydrocarbons to the ultimate carcinogens, including polycyclic aromatic hydrocarbon quinones (Shimada, 2006; L’Heritier et al., 2014). In contrast to enhanced 2-hydroxylation of parent estrogens, which has been associated with a reduced risk of postmenopausal breast cancer (Ziegler et al., 2015), 4-hydroxylation is generally considered a genotoxic pathway that has shown significant carcinogenic properties (Bolton, 2011; Snelten et al., 2012; Cavalieri and Rogan, 2014). Potentially, estrogen quinones could be eliminated by the detoxification enzymes NAD(P)H-quinone oxidoreductase (NQO1) and glutathione-S-transferase, which are regulated through the Nrf2/Keap1/antioxidant response element (ARE) pathway (Figs. 33 and 35). However, there is no direct evidence that these quinones are substrates for the detoxification enzymes, although induction of these enzymes could be considered generally cytoprotective (Chandrasena et al., 2008). Many feedback loops exist between ER, AhR, and Nrf2 pathways (Kohle and Bock, 2007; Swedenborg and Pongratz, 2010); however, as mentioned above, ER signaling crosstalk is beyond the scope of this review.

C. Inflammatory Pathway

Botanicals could also counteract enhanced levels of inflammatory mediators that fuel estrogen chemical carcinogenesis in the breast (Fig. 36) (Howe, 2007; Kamel et al., 2012; Vona-Davis and Rose, 2013). Cytokine secreting macrophages promote the initiation, progression, and metastasis of cancer (Obeid et al., 2013). They upregulate both aromatase and P450 1B1 expression, leading to enhanced genotoxic 4-hydroxylation products and increased DNA damage (Kamel et al., 2012; Vona-Davis and Rose, 2013). Furthermore, inflammatory mediators (e.g., NF-κB, iNOS, COX-2, IL-1β) are often overexpressed in breast cancer tissues, in particular from hormone receptor negative breast cancer, and these mediators are correlated with poor prognosis (Harris et al., 2014). Many inflammatory proteins, such as COX-2, iNOS, and IL-1β, are regulated by the transcription factor NF-κB (Samadi et al., 2015). Numerous botanicals have been reported to inhibit NF-κB activation and/or to inhibit certain inflammatory pathways, such as COX-2, leading to prevention of inflammatory-mediated effects (Izzi et al., 2012).

D. Epigenetic Pathway

Finally, recent evidence suggests that epigenetic pathways can play a role in estrogen carcinogenesis (Fig. 37) (Giacinti et al., 2006; Hervouet et al., 2013; Basse and Arock, 2015). DNA methylation catalyzed by DNA methyltransferases (DNMT), posttranslational histone modification catalyzed by histone deacetylases, histone acetylases (HATs), histone methyltransferases, and histone demethyltransferases can all be involved in the carcinogenic process. As a result, phytochemicals that could interfere with these pathways might have chemopreventive effects through epigenetic modulations (Gerhauzer, 2012; 2013; Byler et al., 2014; Guo et al., 2015a). In summary, estrogen carcinogenesis involves 1) hormonal, 2) chemical, 3) inflammation, and 4) epigenetic pathways (Fig. 33). Many botanicals that are used for postmenopausal women’s health have been described to interfere with all or most of these four pathways, and examples of botanicals with these properties are reviewed below.

E. Isoflavone-containing Botanicals (Red Clover, Soy)

Red clover (Trifolium pratense) and soy (glycine max) contain estrogenic bioactive isoflavones, genistein and
daidzein as discussed in section IV.A.2.a (Fig. 24). The gut metabolite of daidzein, equol, is reported to be more estrogenic and ERβ selective than daidzein (Jiang et al., 2013; van der Velpen et al., 2013). In addition to their estrogenic properties, some epidemiological data suggest that these isoflavones might contribute to the lower incidence of breast cancer in Japanese women, who eat a soy-rich diet (Adlercreutz, 2002; Yamamoto et al., 2003). Therefore, many in vitro and in vivo studies have analyzed the chemopreventive activities of genistein in particular (Russo et al., 2016). However, well-designed clinical trials analyzing the cancer preventive activity of genistein and other isoflavones or soy/red clover extracts are scarce. Isoflavonoids might modulate estrogen carcinogenesis through the hormonal, chemical, inflammatory, and epigenetic pathways (Dietz and Bolton, 2013; Guo et al., 2015a). Genistein in particular is a pleiotropic compound with a multitude of biological activities (Russo et al., 2016) that might modulate estrogen carcinogenesis. Whether isoflavones have breast cancer preventive properties is still a controversial topic and needs to be further analyzed in clinical trials.

1. Hormonal Pathway. In vitro studies revealed that isoflavones, such as genistein (IC$_{50}$ = 3.6 μM) and biochanin A (IC$_{50}$ = 25 μM), are moderate inhibitors of the estrogen synthesizing enzyme aromatase (van Meeuwen et al., 2007). More potent aromatase inhibitors have been designed from the isoflavone scaffold (Bonfield et al., 2012). Genistein and daidzein (Fig. 24) have also been reported to inhibit other steroidogenic enzymes in

Fig. 33. Multitargeted modulation of estrogen carcinogenesis by botanicals. Estrogen carcinogenesis involves numerous pathways: (1) Hormonal (Fig. 23); estrogen binds to ERα, which activates EREs to increase proliferation. (2) Chemical (Figs. 34, 35); the aryl hydrocarbon receptor (AhR) is activated by AhR agonists, which increases P450 1A1 (benign pathway) and P450 1B1 (genotoxic pathway). Additionally, Nrf2-secondMaf binding to the antioxidant response element (ARE) increases NQO1 and phase II enzymes that detoxify genotoxic estrogen o-quinones, which initiate genotoxicity through DNA adducts and ROS produced from redox cycling between the catechol and estrogen-o-quinones. (3) Inflammatory (Fig. 36); inflammatory biomarkers, such as cytokines, increase aromatase expression, thus, increasing estrogen and feeding both the chemical and hormonal pathway. Cytokines, derived from chronic inflammation, macrophages or adipocytes, reportedly suppress P450 1A1, yet increase P450 1B1, most likely through the inflammatory mediator NF-κB. Cytokines also increase expression of genes (i.e., NF-κB, iNOS, COX-2) in epithelial and malignant cells that are often overexpressed in breast cancer patients. (4) Epigenetic (Fig. 37); epigenetic events through ERE inhibit expression of P450 1A1 by encouraging hypermethylation of its promoter, whereas having no significant effect on P450 1B1 expression. Green arrows represent potential positive effects of botanicals, whereas red arrows represent negative effects in each pathway.
the micromolar range, such as 3β-hydroxysteroid dehydrogenase (CYP21), which might ultimately result in lower estradiol levels (Hasegawa et al., 2013). However, other investigations describe genistein as an inducer of aromatase expression/activity in extragonadal cells, which might lead to enhanced local estrogen concentrations (Edmunds et al., 2005; Ye et al., 2009a; van Duursen et al., 2013). Genistein, daidzein, and 6S-equol are preferential ERβ agonists with nanomolar potency, but at higher concentrations, they have ERα activities (Jiang et al., 2013). Because ERβ reduces ERα-induced cell proliferation, the safety of these isoflavones likely depends on their concentrations. In the micromolar range, genistein is a selective protein tyrosine kinase inhibitor, which might lead to reduction of cell growth through inhibition of core signaling tyrosine kinases, such as epidermal growth factor receptor, insulin receptor, and others (Russo et al., 2016). For example, in an ERβ-positive breast cancer cell line, genistein inhibited human epidermal growth factor 2 (HER2) overexpression and HER2 phosphorylation activity, likely through inhibition of its tyrosine kinase activity at concentrations >1 μM (Sakla et al., 2007; Russo et al., 2016). A recent study illustrated the distinct proliferative effects of genistein on different breast cancer cell types (Pons et al., 2016). In cell lines mainly expressing ERα, genistein lead to cell proliferation, whereas in ERβ-expressing cells, genistein treatment had no effect. These studies illustrate that genistein has different effects on the hormonal pathway depending on concentration, ER status, and breast cell type. This might explain some of the conflicting results obtained in breast cancer cells or in animal experiments studying estrogen sensitive tissues.

Several animal and clinical studies analyzed the effect of isoflavones on endometrial and mammary tissue with controversial outcomes (Dietz and Bolton, 2013). Some in vivo experiments suggest that genistein suppresses mammary carcinogenesis (Constantinou et al., 2001; Sahin et al., 2011); however, many recent in vivo investigations found that it promotes carcinogenesis in breast tissue and enhances metastasis formation (Ju et al., 2006; Yang et al., 2015). Three animal studies demonstrated that genistein stimulates mammary gland growth and enhances the growth of breast cancer cells (MCF-7) in animals (Hsieh et al., 1998; Allred et al., 2004; Ju et al., 2006). These reports show that isoflavones of red clover/soy have the potential to reduce and/or enhance the hormonal-related carcinogenic effects of endogenous estrogens. However, the activity of the whole red clover extract or soy supplementation might be distinct from the activity of the
isolated isoflavones. For example, uterotrophic activities have been described for genistein (Diel et al., 2004a) but not for the red clover extract (Overk et al., 2008).

Most clinical trials suggest that isoflavones in dietary supplements are safe and do not show estrogenic effects on breast or endometrial tissues. For example, in one clinical trial that used a standardized (26 mg biochanin A, 16 mg formononetin, 1 mg genistein, and 0.5 mg daidzein) red clover extract in women (age 49–65 years), the extract did not increase breast density over 1 year (Atkinson et al., 2004). A clinical study (up to 3 years) with postmenopausal women suggested that purified genistein (54 mg/day) is safe with respect to breast and endometrial proliferation (Taylor et al., 2009). In contrast to the placebo group, the genistein arm showed a statistically significant decrease in endometrial thickness at the 36-month follow up. Genistein also significantly decreased sister chromatid exchanges in peripheral blood lymphocytes isolated from postmenopausal study participants after administration of 54 mg/day genistein for 1 year in a randomized placebo-controlled study (Atteritano et al., 2008). A clinical study (up to 3 years) with postmenopausal women suggested that purified genistein (54 mg/day) is safe with respect to breast and endometrial proliferation (Taylor et al., 2009). In contrast to the placebo group, the genistein arm showed a statistically significant decrease in endometrial thickness at the 36-month follow up. Genistein also significantly decreased sister chromatid exchanges in peripheral blood lymphocytes isolated from postmenopausal study participants after administration of 54 mg/day genistein for 1 year in a randomized placebo-controlled study (Atteritano et al., 2008).

Fig. 35. Nrf2 pathway. Under normal conditions Nrf2 is associated with Keap1 in the cytosol and ubiquitinated by Cul3, causing Nrf2 proteasomal degradation. Electrophilic botanicals covalently modify cysteines in Keap1, leading to a conformational change; inhibition of Cul3-mediated Nrf2 ubiquitination, accumulation, and nuclear translocation of Nrf2; and upregulation of ARE-regulated detoxification enzymes.

isolated isoflavones. For example, uterotrophic activities have been described for genistein (Diel et al., 2004a) but not for the red clover extract (Overk et al., 2008).

Most clinical trials suggest that isoflavones in dietary supplements are safe and do not show estrogenic effects on breast or endometrial tissues. For example, in one clinical trial that used a standardized (26 mg biochanin A, 16 mg formononetin, 1 mg genistein, and 0.5 mg daidzein) red clover extract in women (age 49–65 years), the extract did not increase breast density over 1 year (Atkinson et al., 2004). A clinical study (up to 3 years) with postmenopausal women suggested that purified genistein (54 mg/day) is safe with respect to breast and endometrial proliferation (Taylor et al., 2009). In contrast to the placebo group, the genistein arm showed a statistically significant decrease in endometrial thickness at the 36-month follow up. Genistein also significantly decreased sister chromatid exchanges in peripheral blood lymphocytes isolated from postmenopausal study participants after administration of 54 mg/day genistein for 1 year in a randomized placebo-controlled study (Atteritano et al., 2008). A clinical study (up to 3 years) with postmenopausal women suggested that purified genistein (54 mg/day) is safe with respect to breast and endometrial proliferation (Taylor et al., 2009). In contrast to the placebo group, the genistein arm showed a statistically significant decrease in endometrial thickness at the 36-month follow up. Genistein also significantly decreased sister chromatid exchanges in peripheral blood lymphocytes isolated from postmenopausal study participants after administration of 54 mg/day genistein for 1 year in a randomized placebo-controlled study (Atteritano et al., 2008).

Soy isoflavone dietary intervention studies with premenopausal women showed no toxicity over a period of 2 years with no effect on breast density as analyzed by mammography (Taylor et al., 2009). Similarly, a randomized, double-blind, placebo-controlled study revealed that consumption of 250 mg of standardized soy extract (100 mg/day isoflavones) by postmenopausal women for 10 months did not influence breast density (Delmanto et al., 2013). The correlation of plasma genistein and daidzein concentrations with breast cancer or benign breast conditions was analyzed in a breast self-examination trial in Chinese women. The subjects included women diagnosed with breast cancer or benign breast conditions and age-matched controls with no known breast disease (Lampe et al., 2007). The results revealed that plasma daidzein and genistein concentrations were significantly higher in controls than in patients with breast cancer or benign breast conditions. These data may indicate selective uptake of the phytoestrogens by ER-positive tumors; however the overall chemopreventive effect of isoflavones on breast cancer is unknown.

However, some clinical studies depict an estrogenic or proliferative effect after consumption of isoflavone-containing dietary supplements. For example, a 2-week dietary supplementation study with soy (45 mg/day) in premenopausal women revealed an estrogenic effect as measured by modulation of estrogen-sensitive genes in nipple aspirate fluid (Taylor et al., 2009). A similar study with soy protein supplementation in premenopausal women suggested an estrogenic effect of soy due to an increase in proliferation of breast epithelium and an enhanced expression of progesterone receptors (Taylor et al., 2009).
A 6-month intervention study using a preparation of mixed soy isoflavones (150 mg genistein, 74 mg daidzein) was performed in healthy, high-risk adult Western women to examine the effect of these isoflavones on breast epithelial proliferation and other biomarkers in the breast tissue (Khan et al., 2012b). The study demonstrated that the isoflavones did not reduce breast epithelial proliferation, suggesting a lack of efficacy for breast cancer prevention. However, among treated premenopausal women, there was a statistically significant increase in the postintervention Ki-67 labeling index after soy supplementation. Gene expression studies demonstrated a mixed pattern, with more genes enhanced in the isoflavone supplementation group that suggested estrogenic activity. Further clinical studies with different concentrations are warranted to obtain a better picture of the hormonal and proliferative activities of isoflavone containing dietary supplements on breast tissue.

2. Chemical Pathway. Isoflavones have been shown to modulate different estrogen metabolism enzymes through a variety of pathways in in vitro and in vivo studies (Mense et al., 2008; Snelten et al., 2012). They modulate the P450 enzymes, P450 1A1 and P450 1B1, through inhibition of enzyme activity and through induction or suppression of their transcription (Wagner et al., 2008; Takemura et al., 2013). Genistein has been demonstrated to decrease P450 1A1/1B1 activity in part through direct inhibition of the enzyme in several assays in the low micromolar range (Roberts et al., 2004; Mense et al., 2008; Scott et al., 2008; Takemura et al., 2013). Similarly, daidzein and equol have been reported to reduce P450 1A1 and 1B1 activity in different cell assays (Roberts et al., 2004; Scott et al., 2008).

CYP1B1 and CYP1A1 are both regulated through the AhR (Fig. 34) (Murray et al., 2014). Two AhR transactivation assays revealed biochanin A and formononetin as good AhR ligands (nM–μM range), whereas genistein, daidzein, and equol had no activity (Medjakovic and Jungbauer, 2008; Bialesova et al., 2015). Biochanin A was confirmed as...
an AhR ligand in a TCDD competitive AhR binding assay (Han et al., 2006). Biochanin A also induced the xenobiotic response element (XRE) activity in the breast cancer cell line MCF-7 (Chan et al., 2003), and at higher concentrations (10–50 μM), it caused a significant induction of CYP1A1 mRNA expression and CYP1 activity (Han et al., 2006), suggesting that biochanin A can increase oxidative estrogen metabolism. In the presence of a strong AhR agonist DMBA, biochanin A (≥5 μM) inhibited DMBA-induced XRE activity, CYP1A1 and CYP1B1 mRNA expression, as well as DMBA-induced P450 1A EROD activity in MCF-7 cells suggesting that biochanin A can act as an AhR agonist (Chan et al., 2003; Han et al., 2006).

Interestingly, genistein and daidzein reduced CYP1A1 mRNA levels and P450 1 activity at low concentrations in MCF-7 cells (Wagner et al., 2008). Because estradiol has been reported to downregulate CYP1A1 (LMCF-7 cells (Wagner et al., 2008). Because estradiol has an estrogenic effect on CYP1A1 mRNA levels and P450 1 activity at low concentrations in MCF-7 cells, it might be explained by their estrogenic effects. At the tested concentrations, CYP1B1 was not influenced by genistein and daidzein. Higher genistein concentrations (5–25 μM) were shown by Wei et al. (2015) to induce CYP1B1 mRNA levels. Genistein also inhibited DMBA-induced XRE-luciferase activity, P450 1 activity, CYP1A1 and 1B1 mRNA expression, and DNA adducts in the micromolar range in MCF-7 and MCF-10A cells (Chan and Leung, 2003; Leung et al., 2009). Only a limited number of in vivo studies have analyzed the influence of isoflavones on estrogen metabolism enzymes with different outcomes. One study analyzing the influence of the mixture of isoflavones on CYP1B1 and CYP1A1 in primate mammary glands and liver tissue did not show any significant effect (Scott et al., 2008). However, significant induction of CYP1A1 was observed after treatment of male Wistar rats with a standardized soybean extract containing 37% isoflavones (100 mg/kg) for 10 days (Mrozikiewicz et al., 2010).

Isoflavones have also been shown to modulate detoxification enzymes that facilitate the elimination of estradiol and its metabolites (Fig. 35) (Dietz and Bolton, 2013). Experiments in human colon cancer cells revealed that genistein (≥0.1 μM) caused significant induction of NQO1 activity, whereas biochanin A was less effective and daidzein and formononetin were inactive (Wang et al., 1998). Genistein induced NQO1 in various cell lines as well as in different tissues in animal studies (Wang et al., 1998; Bianco et al., 2005; Froyen et al., 2009; Wiegand et al., 2009). Mechanism of action studies in ER-positive cell lines demonstrated that genistein might influence NQO1 through ER-dependent and -independent pathways (Bianco et al., 2005; Wagner et al., 2008; Kaspar and Jaiswal, 2010). It has been shown that genistein (1 μM) and daidzein (10 μM) reduced NQO1 mRNA levels and catechol-O-methyltransferase mRNA and activity similar to estradiol in MCF-7 cells likely through an ERα-Nrf2-mediated mechanism (Wagner et al., 2008). However, in ERβ-positive cells, the isoflavones upregulated NQO1 mRNA through an ERβ-Nrf2-mediated mechanism (Bianco et al., 2005; Froyen and Steinberg, 2011). These variable results suggest that the NQO1 induction potential of genistein may be dependent on the cell type and ER status.

The influence of isoflavones on other detoxification enzymes might be less pronounced. Although genistein induced hepatic NQO1 activity, it did not induce the activity of other detoxification enzymes (glutathione-S-transferase, catalase, glutathione peroxidase, superoxide dismutase) (Wiegand et al., 2009). However, in a topical inflammation model, in which 1 or 2 μg of a soy isoflavone product was administered, the activity of the detoxification enzymes catalase and superoxide dismutase were induced, as well as glutathione levels (Khan et al., 2012a). An in vivo study in Sprague-Dawley rats (7 days) analyzed the effect of biochanin A on the Phase II enzyme sulfotransferase that is involved in the metabolism of estradiol and detoxification of various carcinogens (Rafogianis et al., 2000; Chen et al., 2010b). The study revealed that biochanin A (10 mg/kg/day) induced the expression and activity of sulfotransferase 1A1 and 2A1 in female rat liver and intestine.

In conclusion, the isoflavones have the potential to modulate estrogen metabolism. Biochanin A and formononetin seem to be AhR agonists and have the highest potential to induce P450 1A1/1B1 (Han et al., 2006; Bialesova et al., 2015). However, in vivo, biochanin A and formononetin are rapidly metabolized to genistein and daidzein, respectively (Fig. 24), and their concentration is likely relatively low (Piersen et al., 2004). Soy supplements contain much less biochanin A and formononetin than red clover extracts (Burdette and Marcus, 2013) and might therefore have a better safety profile with respect to estrogen metabolism. In general, the influence of genistein on the chemical pathway is probably cell and ER-status dependent. Therefore, more in vivo studies are warranted to analyze whether soy and red clover would reduce or enhance genotoxic estrogen metabolism.

3. Inflammatory Pathway. Anti-inflammatory activities have been described for soy, red clover, and their isoflavones in in vitro and in vivo studies (Banerjee et al., 2008; Seibel et al., 2009; Masilamani et al., 2012; Nagaraju et al., 2013; Ganai et al., 2015). For example, a red clover extract (40% isoflavones) and isolated isoflavones reduced the proinflammatory cytokines IL-6 and TNF-α in lipopolysaccharide (LPS)-induced macrophages (Mueller et al., 2010). Biochanin A exhibited the strongest TNF-α inhibition (IC₅₀ = 6 nM), followed by genistein (IC₅₀ = 40 nM), whereas IL-6 was most efficiently inhibited by genistein and equal (IC₅₀ = 8 and 6 nM, respectively). Other studies reported the reductive inflammation of inflammatory cytokines by genistein, such as IL-4, IL-5, interferon-γ, in a murine model of asthma (Gao et al., 2012).
Various studies demonstrated the ability of isoflavones to reduce NF-κB pathways in different cell lines in the micromolar range (Gong et al., 2003; Kole et al., 2011; Masilamani et al., 2012; Wu et al., 2015b). Further analysis revealed that one mechanism through which genistein might reduce nuclear translocation of NF-κB is likely the inhibition of kinase pathways leading to a reduced phosphorylation of the NF-κB inhibitory protein IκBα (Gong et al., 2003; Masilamani et al., 2012; Ganai et al., 2015) or to a decreased phosphorylation of the NF-κB subunit p65 (Chung et al., 2014). Similarly, biochanin A has been shown to inhibit LPS-induced NO, IL-6, IL-1β, and TNF-α production in macrophages through prevention of phosphorylation and degradation of IκBα (Kole et al., 2011). In certain cell lines, a role for the ER in inhibiting NF-κB pathways has been postulated (Sas et al., 2012) and that isoflavones, such as genistein, might reduce inflammatory responses through their ER binding activity (Dijsselbloem et al., 2004).

Various in vitro and in vivo studies demonstrated that isoflavones repress or inhibit COX-2 activity in the micromolar range (Lam et al., 2004; Horia and Watkins, 2007; Seibel et al., 2009; Mueller et al., 2010; Chung et al., 2014). Comparison of the COX-2 inhibiting potential of the four isoflavones (Fig. 24) in murine macrophages showed genistein had the highest activity at 1 μM compared with 10 μM for biochanin A and 40 μM for formononetin and daidzein (Lam et al., 2004). Genistein (1 μM) also significantly inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced prostaglandin E2 (PGE2) synthesis in ER negative breast cancer cells (MDA-MB-231) (Horia and Watkins, 2007). In addition, it significantly reduced the invasion capacity of this cell line at 10 μM, suggesting a chemopreventive potential of genistein in ER negative breast cancer cells. Pretreatment of human nontumorigenic breast epithelial cells (MCF-10A) with genistein (>46 μM) reduced TPA-induced COX-2 expression and PGE2 synthesis through reduction of TPA-induced transcriptional activity of NF-κB (Chung et al., 2014). Genistein also reduced COX-2 expression in animal models of inflammation (Hwang et al., 2009; Willenberg et al., 2015). Because COX-2 is reported to be upregulated in breast cancer and epidemiological studies suggest a protective effect of COX inhibitor drugs on breast cancer (Howe, 2007), further in vivo studies are needed to determine if long-term treatment with isoflavone containing dietary supplements might modulate COX-2 in the breast tissue.

In a 2-year soy intervention study, 183 premenopausal women consumed either two daily soy servings containing 50 mg of isoflavones (aglycone equivalents) or their regular diet (Maskarinec et al., 2009). Serum samples were obtained in regular intervals and were analyzed for the inflammatory markers IL-6, C-reactive protein, leptin, and adiponectin by enzyme-linked immunosorbent assay. No significant effect of the soy food was determined; however, the leptin value increased in the control but not in the soy group. In a single-blind, randomized, controlled trial, 31 postmenopausal women received either three servings of soy milk or reduced fat dairy milk for 4 weeks (Beavers et al., 2009). Plasma markers of inflammation and oxidative stress (TNF-α, IL-6, IL-1β, COX-2, superoxide dismutase, and glutathione peroxidase) were determined before and after supplementation; however, no significant effects of the soy milk intervention were observed for any of these markers.

In conclusion, although there are clear anti-inflammatory activities reported for isoflavones from in vitro studies, the in vivo experiments and clinical trials analyzing the inflammatory pathways are less conclusive (Beavers et al., 2009; Maskarinec et al., 2009; Willenberg et al., 2015). More clinical trials will be necessary to evaluate the anti-inflammatory potential of isoflavones, soy, and red clover dietary supplements for their potential clinical application.

4. Epigenetic Pathway. Recent studies indicated that isoflavones might exert cancer chemopreventive effects by targeting epigenetic mechanisms (Guo et al., 2015a; Hwang and Choi, 2015). Various in vitro studies demonstrated that genistein suppresses DNA methylation in breast cancer cells, possibly leading to increased mRNA expression of tumor suppressor genes (Guo et al., 2015a). For example, genistein (Fig. 24) has been shown to decrease mRNA levels and protein expression of DNA methyltransferase 1 (DNMT1) in MCF-7 cells. DNMT1 has been reported to be upregulated in breast cancer tissue (Mirza et al., 2013). Also, genistein, has been reported to reactivates ERα expression and resensitize ERα-dependent cellular responses to E2 in ERα-negative breast cancer cells, MDA-MB-231, in the micromolar range through epigenetic effects (Li et al., 2013c). In addition, genistein and daidzein in the micromolar range decreased hypermethylation of the oncosuppressor genes, tumor suppressor gene 1 and tumor suppressor gene 2, resulting in restored activity of these genes in different breast cell lines (Bosviel et al., 2012). Treatment with a genistein-enriched diet (250 mg/kg genistein) inhibited breast cancer development in a breast cancer xenograft model perhaps due to epigenetic regulation of the tumor suppressor genes p21 and p16 (Li et al., 2013a).

Isoflavones might have protective effects toward breast carcinogenesis when a diet rich in soy products is consumed early in life (Warri et al., 2008). This is in part based on the protective effect of a lifelong high-soy diet on breast cancer in Asian women. On the basis of this information, an in vivo study analyzed the influence of lifelong exposure to an isoflavone-rich diet on mammary gland proliferation, other estrogen sensitive endpoints, and on epigenetic markers (Blei et al., 2015). The authors concluded that isoflavones might alter the morphology of the mammary gland during pubertal breast growth and epigenetic modulation might play an important role. These effects might ultimately have
an influence on the likelihood of breast carcinogenesis later in life; however, further studies are necessary to support this theory. In general, epidemiological studies suggest that soy consumption is associated with less breast cancer risk in Japanese women with an enriched soy diet (Yamamoto et al., 2003); however, the correlation between isoflavone intake and breast cancer risk is less clear in American women. The association between dietary isoflavone intake with breast cancer risk was analyzed using population-based, observational data from the Multiethnic Cohort Study (MEC) in 84,450 mostly postmenopausal American women, who were categorized based on their isoflavone intake (highest consumed amount: 20.3–178.7 mg/day) (Morimoto et al., 2014). After a mean follow up of 13 years, no statistical association between dietary isoflavone intake and overall breast cancer risk was observed. This study is in agreement with other epidemiological prospective studies suggesting that high soy intake in Asian women (around 25 and 50 mg of isoflavones) starting earlier in life shows a significant trend of breast cancer risk reduction; however, studies with Western women consuming a low soy diet do not show a significant association between dietary isoflavone exposure and breast cancer risk (Wu et al., 2008a; Dong and Qin, 2011).

In conclusion, numerous studies have shown that isoflavones, in particular genistein, might modulate estrogen carcinogenesis through hormonal, chemical, inflammatory, and epigenetic pathways. The data analyzing the influence of isoflavones on cell proliferation (hormonal) and on estrogen metabolism enzymes (chemical) reveal conflicting results, suggesting that isoflavones might enhance or decrease estrogen carcinogenesis through both hormonal and chemical pathways. The concentrations and cell type may play an important role whether isoflavones reduce or increase estrogen carcinogenesis. There is clear evidence mostly from in vitro studies that isoflavones, in particular genistein, have anti-inflammatory properties that might decrease estrogen carcinogenesis in the breast. However, dietary in vivo studies show conflicting results and it is not clear whether the bioavailability of genistein and of the other isoflavones in dietary supplements are sufficient to exert significant clinical anti-inflammatory activity. Epigenetic effects with subsequent reactivation of tumor suppressor genes and other genes have been shown (e.g., genistein). Some in vivo studies propose that lifelong exposure to isoflavones might modulate mammary gland development during puberty, potentially leading to breast cancer prevention. Overall, clinical studies often indicate no breast cancer preventive effect with low isoflavone intake in the diet during adulthood in Western cultures. However, some studies show a protective effect when isoflavones are enriched in the diet throughout life as in the case of Asian populations. Future animal and clinical studies are needed to determine if isoflavones are safe and whether they have the ability to elicit chemopreventive properties at clinically relevant concentrations.

F. Humulus lupulus (Hops)

In addition to the estrogenic properties of hops, which are mediated by the potent ERα phytoestrogen 8-PN (Fig. 26) (section IV.A.2.a), chemopreventive properties have been described for hop extracts and especially for the major prenylated polyphenol, the chalcone xanthohumol (XH) (Fig. 26) (Chadwick et al., 2004; Plazar et al., 2007). XH is an electrophilic compound that exerts multiple chemopreventive effects at least in part through binding to sulphhydryl groups in proteins, such as Keap1 (Liu et al., 2005), leading to the induction of the detoxification enzyme NQO1 (Fig. 35) (Dietz et al., 2005a, 2013). In addition, XH has been shown to induce apoptosis (Strathmann et al., 2010) and to exhibit anti-inflammatory activities (Harikumar et al., 2009; Dorn et al., 2013). Some in vitro and in vivo studies suggest that hop extracts might influence the hormonal, chemical, and inflammatory pathways of estrogen carcinogenesis. Data on the potential influence of hops and its bioactive compounds on the epigenetic pathway are currently not available. Clinical investigations that analyze the chemopreventive properties in human are also lacking.

1. Hormonal Pathway. As outlined in section IV. A.2.b, 8-PN (Fig. 26) is a potent nanomolar ERα agonist (Overk et al., 2005; Helle et al., 2014). Various in vitro and in vivo studies demonstrate proliferative activities on breast cells/tissue or uterotrophic activities (Diel et al., 2004b; Overk et al., 2008). These proliferative activities might enhance hormonal estrogen carcinogenesis and may interfere with concurrent breast cancer treatments (van Duursen et al., 2013). However, XH has been reported to have antiproliferative activities in the micromolar range in several cancer cell lines (Vanhoecke et al., 2005; Yoshimaru et al., 2014). For example, in ERα-positive cells, XH suppressed E2 signaling through reactivation of the tumor suppressor protein prohibitin 2 (Yoshimaru et al., 2014). XH has also been reported to inhibit cell invasion through upregulation of the epithelial cadherin/catenin complex in MCF-7 cells (Vanhoecke et al., 2005). Because the concentration of XH in hops extracts is usually much higher than that of 8-PN (van Breeemen et al., 2014), XH might reduce the proliferative activities of 8-PN in the whole hop extract. For example, a hops extract showed estrogenic activities in vitro; however, in vivo studies did not reveal uterotrophic activities, suggesting that either the bioavailable 8-PN concentrations were not high enough or that the extract may contain various counteracting phytoconstituents such as XH or phytoprogestins (Overk et al., 2008). In general, 8-PN is a minor compound in hops, but it can accumulate in vivo through metabolism of IX by P450s or intestinal bacteria (Fig. 26) (Possemiers et al., 2006; van Breeemen et al., 2014). The overall estrogenic properties are therefore highly dependent on the composition of the hops
Aromatase inhibition has also been reported for 8-PN (300 nM) in microsomes of human placental tissue or fibroblasts from healthy human mammary tissue (van Meeuwen et al., 2008). Similarly, in a human adrenal gland cell line, H295R, 8-PN was a potent aromatase inhibitor with an IC50 of 0.1 μM (van Duursen et al., 2013). Interestingly, coculture of H295R cells with MCF-7 cells led to decreased estradiol concentrations and predominantly to an increased progesterone and 17α-OH-progesterone level. In breast cancer cells, 8-PN showed the highest aromatase inhibiting activity compared with IX and XH with an IC50 of 0.08 μM (Monteiro et al., 2007). XH inhibited aromatase with a lower IC50 of 3.2 μM, and IX showed the weakest activity (IC50 = 25.4 μM).

2. Chemical Pathway. Several hop polyphenols (Fig. 26) have been analyzed for their potential to inhibit P450 1A1 and 1B1, which are involved in estrogen metabolism (Henderson et al., 2000). Several of these compounds showed significant inhibitory potential for these P450 enzymes at 10 μM. However, 8-PN was also able to moderately induce CYP1A2 mRNA levels (Gross-Steinmeyer et al., 2009). Recently, P450 1A1 and 1B1 inhibiting potential has been confirmed for IX, 8-PN, XH, and 6-PN with IC50 values in the high nanomolar to low micromolar range (Wang et al., 2016). 8-PN and 6-PN have also been shown to be agonists for the AhR receptor, resulting in an increase in AhR-mediated XRE-luciferase activity in HepG2 and MCF-7 cells. 6-PN also gave a significant increase in CYP1A1 gene expression, P450 1 activity, and estrogen 2-hydroxylation in MCF-10A and MCF-7 cells (Fig. 34). These data suggest that hops favors induction of the nongenotoxic 2-hydroxylation pathway in breast cells (Wang et al., 2016). Another study reported that a hop extract inhibited estrogen-induced malignant cell transformation of MCF-10A cells, suggesting that hops might have chemopreventive activity potentially through attenuation of the genotoxic estrogen metabolism pathway (Hemachandra et al., 2012).

Hops and its major Michael acceptor, XH, also influence detoxification enzymes. They have been shown to induce NQO1 activity in murine hepatoma cells, leading to prevention of menadione-induced DNA damage at low micromolar concentrations (Dietz et al., 2005a). XH has also been shown to increase the levels of Nrf2, GSTA, and GSTP in human hepatocarcinoma HepG2 cells, whereas in normal hepatocytes it increased the levels of Nrf2, GSTs, HO-1, and NQO1 in addition to p53 (Krajka-Kuzniak et al., 2013). XH also upregulated the transcription of NQO1 and HO-1 in mouse microglial cells via the Nrf2 pathway (Lee et al., 2011a). The in vivo NQO1-inducing potential by hops and XH has been confirmed in liver tissue of Sprague-Dawley rats (Dietz et al., 2013). These data suggest the potential of hops and its abundant Michael acceptor, XH, in modulating cytoprotective enzymes leading to chemoprevention.

3. Inflammatory Pathway. Various in vitro and in vivo studies describe anti-inflammatory activities for hop extracts (Saugspier et al., 2012; Starkel et al., 2015) and XH (Hougee et al., 2006; Lupinacci et al., 2009; Dorn et al., 2012). Lupinacci et al. (2009) reported that a hop extract (0.1 μg/ml) significantly inhibited the production of the proinflammatory chemokine monocyte chemotactrant protein-1 in LPS-activated RAW 264.7 mouse macrophages. Bioassay guided fractionation of the extract revealed XH (2.5 μg/ml) as the major anti-inflammatory compound (Lupinacci et al., 2009; Dietz and Bolton, 2013). XH (micromolar range) inhibited the activation or binding of the transcription factor NF-κB in macrophages, glia cells, hepatic stellate cells, or breast cancer cells, thus reducing the induction of proinflammatory genes and cytokines (Harikumar et al., 2009; Cho et al., 2010; Lee et al., 2011a; Dorn et al., 2012). Studies in mouse microglial cells showed that the anti-inflammatory activity of XH depended on the transcription factor Nrf2, in addition to NF-κB (Lee et al., 2011a). Other mechanism of action studies showed that XH might inhibit TNF-induced IkBα phosphorylation and degradation, likely through interacting with cysteine residues of IKK and p65, thus leading to suppression of nuclear translocation of p65 and inhibition of NF-κB pathways (Harikumar et al., 2009). In vivo anti-inflammatory activities have also been reported for XH (Dietz and Bolton, 2013; Gupta et al., 2014). In a chronic dermatitis model in the mouse ear, topical XH treatment reduced the degree of ear thickening induced by oxazolone, suggesting that XH reduces skin inflammation (Cho et al., 2010). In two animal models of liver injury and inflammation, feeding of XH reduced mRNA levels of hepatic inflammatory markers (e.g., IL-1α, monocyte chemotactrant protein-1) (Dorn et al., 2012, 2013). The mechanism seemed at least in part through decrease of NF-κB activity (Dorn et al., 2012). Interestingly, oral administration of XH (100 μM) to nude mice inoculated with MCF-7 cells resulted in a significant decrease in NF-κB activity, reduced phosphorylated IkBα staining, and a decrease in the inflammatory interleukin IL-1β, which is often increased in breast cancer (Monteiro et al., 2008). Although the tumor weights between the control and XH group were not significantly different, XH did significantly increase the amount of apoptotic cells and decreased microvessel density in the tumors (Monteiro et al., 2008). A spent hops extract, supplemented to the diet of 5-week-old pigs for 4 weeks, also led to a significant decrease of the inflammation marker IL-1β in the duodenum, ileum, and colon (Fiesel et al., 2014).

COX-2 is another inflammatory marker in breast cancer that has been shown to be inhibited by many phytochemicals. COX-2 inhibition has been demonstrated for a hop extract and XH (Gerhäuser et al., 2002; Hougee et al., 2006). A hops CO2 extract inhibited...
PGE2 production in LPS-stimulated peripheral blood monocytes (IC$_{50}$ = 3.6 μg/ml) likely through inhibition of COX-2 (IC$_{50}$ = 20.4 μg/ml) (Hougee et al., 2006). Mice treated with this hop extract showed decreased production of PGE2 in a zymosan-induced acute arthritis model; however, the extract did not reduce joint swelling (Hougee et al., 2006). XH, but not IX, moderately inhibited COX-1 and COX-2 activity in microsomal fractions (IC$_{50}$ = 16.6 μM and 41.5 μM, respectively) (Gerhäuser et al., 2002), suggesting that other hop compounds might add to the COX inhibiting activity of hops extracts.

4. Epigenetic Pathway. The influence of hops or its compounds on epigenetic pathways has not been examined in detail. One study analyzed protein targets of the electrophile XH in the breast cancer cell line MCF-7/6 (Wyns et al., 2012). Immunoprecipitation experiments using a mouse-XH-antibody revealed that XH binds to proteins of the histone H2A family. Therefore, XH may exert epigenetic effects through modification of histones that could influence gene expression, potentially leading to chemopreventive effects.

In summary, the in vitro and in vivo studies suggest that hops may modulate estrogen carcinogenesis. 8-PN elicits estrogenic, proliferative, and aromatase inhibitory activities in the nanomolar range; however, other hops phytochemicals might counteract these proliferative activities. The CYP inhibiting activity of 8-PN might also influence estrogen metabolism, although much higher concentrations are needed (micromolar) for these effects, which may not be clinically relevant. 6-PN has been shown to be a potent inducer of P450 1A1, which catalyzes the benign estrogen 2-hydroxylation pathway leading to lower estrogen levels. Hops and XH have been shown to exert chemopreventive activity in vitro and in vivo through the Keap1-Nrf2 pathway, resulting in the induction of detoxification enzymes such as NQO1 and HO-1. Anti-inflammatory activities of hops and XH have been reported in vitro and in vivo through modulation of NF-κB, COX-2, and prostaglandins. Hops and XH might have the potential to exhibit chemoprevention via epigenetic mechanisms, which needs further studies. Although a human pharmacokinetic study demonstrated the bioavailability of the hops compounds 8-PN and XH (van Breemen et al., 2014), clinical studies are needed to analyze the chemopreventive activities of hops. It is also important to define whether the concentrations of the bioactive compounds in standardized hop dietary supplements are sufficient to achieve chemopreventive effects in women.

G. Glycyrrhiza Species (Licorice)

As discussed in section IV.A.2.c, estrogenic properties have been reported for several licorice species and liquiritigenin (Fig. 27) is believed to be one of the estrogenic compounds (Hajirahimkhan et al., 2013b). Some studies suggest licorice could modulate proliferation in estrogen-sensitive cells/tissues, which could prevent hormonal carcinogenesis (Mersereau et al., 2008; Tang et al., 2015). Licorice also contains electrophilic compounds such as isoliquiritigenin and licochalcone A that might induce chemoprevention through activation of apoptotic pathways, anti-inflammatory effects, and inhibition of oxidative estrogen metabolism (Webb et al., 1992; Jo et al., 2004; Takahashi et al., 2004; Cuendet et al., 2006; Wu and Hsieh, 2011; Tsai et al., 2014; Dunlap et al., 2015; Peng et al., 2015; Tang et al., 2015). Involvement of the three medicinally used species of licorice (G. glabra, G. uralensis, and G. inflata) and their compounds in various mechanisms of breast cancer prevention is reviewed below.

1. Hormonal Pathway. It has been shown that extracts of Glycyrrhiza glabra and G. uralensis stimulated MCF-7 (ER+) cell growth at low concentrations (Dong et al., 2007; Hu et al., 2009). In contrast, G. uralensis was reported to have antiproliferative effects in MCF-7 breast cancer cells at higher concentrations (Jo et al., 2004, 2005). The estrogenic compound liquiritigenin did not enhance proliferation of MCF-7 (ER+) xenografts or induce uterine weight in nude mice (Mersereau et al., 2008), likely because of its ERβ selectivity. The marker compound in G. glabra, glabridin (Fig. 27), was shown to stimulate ER-dependent cell growth at concentrations lower than 10 μM and to inhibit cell growth at concentrations higher than 15 μM (Tamir et al., 2000). Selective estrogen receptor modulator-like activities of isoliquiritigenin and liquiritigenin have also been reported in an array of cell based assays (Boonmuen et al., 2016). Finally, isoliquiritigenin inhibited aromatase in MCF-7 cells stably transfected with CYP19 (MCF-7aro) and deterred the growth of MCF-7aro xenograft tumors in ovariectomized athymic mice when administered in the diet (Ye et al., 2009b).

2. Chemical Pathway. Licorice species and its bioactive compounds have been shown to differentially regulate estrogen metabolism and thus may have varied effects on breast cancer prevention. It was shown that G. glabra and G. uralensis as well as isoliquiritigenin increased the genotoxic estrogen 4-hydroxylation pathway through enhanced AhR-mediated induction of P450 1B1 activity in MCF-10A cells (Dunlap et al., 2015). However, in the same study G. inflata and its specific compound licochalcone A (Fig. 27) inhibited estrogen metabolism by antagonizing AhR and blocking XRE at the promoter region of CYP1B1 (Dunlap et al., 2015). When DMBA or TCDD were used as the AhR agonists in MCF-7 cells, isoliquiritigenin reduced AhR translocation to the nucleus and diminished AhR interaction with XREs leading to downregulation of DMBA and TCDD-mediated induction of CYP1A1, 1A2, and 1B1 (Wong et al., 2014). Similarly, G. glabra extract suppressed the tumorigenic effects of TCDD by downregulating AhR, arylhydrocarbon receptor nuclear translocator, and CYP1A1 genes and inducing cell cycle
arrest in MCF-7 cells (Chu et al., 2014). These data suggest that different species of licorice could have a variety of effects on estrogen metabolism, which further emphasizes the importance of authentication of material and standardization to bioactive compounds.

Various licorice species have also been shown to differentially modulate detoxification pathways. *G. uralsensis* was reported to induce Nrf2-mediated genes in hepatoma cells and animal tissues (Wu et al., 2011). In a comparative analysis, *G. glabra*, *G. uralensis*, and *G. inflata* induced NQO1 dose dependently in murine hepatoma (hepa1c1c7) and breast epithelial (MCF-10A) cells (Hajirahimkhan et al., 2015). However, when *G. glabra* and *G. uralensis* were administered orally to female rats, no NQO1 induction was observed in liver, whereas *G. glabra* had a slight but significant NQO1 induction in mammary tissue (Hajirahimkhan et al., 2015). It was shown that the common Michael acceptor of licorice species, isoliquiritigenin activated NQO1 dose dependently in vitro but failed to induce this enzyme in liver and mammary glands of the female rats when administered orally (Hajirahimkhan et al., 2015). Other studies showed slight increase in NQO1 at very high doses of isoliquiritigenin, but the effect did not lead to the inhibition of mammary tumor growth (Cuendet et al., 2006, 2010). These observations with isoliquiritigenin could be associated with its conversion to the estrogenic compound liquiritigenin as discussed earlier and also to the low bioavailability of isoliquiritigenin in vivo (Hajirahimkhan et al., 2013b, 2015; Simmler et al., 2013). Licochalcone A in *G. inflata* is also a Michael acceptor and has been shown to induce NQO1 in hepa1c1c7 and MCF-10A cells (Kondo et al., 2007a; Hajirahimkhan et al., 2015; Simmler et al., 2015a).

These data suggest that various species of licorice could differentially modulate the chemical estrogen carcinogenesis pathway.

### 3. Inflammatory Pathway.

Licorice has been traditionally used for several ailments such as coughs or ulcer that could be associated with inflammation (Asl and Hosseinzadeh, 2008). There are also numerous scientific reports about the anti-inflammatory effects of licorice and compounds in different organs such as lung, skin, nervous system, liver, and cardiovascular system to name a few (Chu et al., 2013; Dohil, 2013; Kim et al., 2013b; Kang et al., 2015; Yu et al., 2015). The role of licorice in preventing breast cancer through modulating inflammatory pathways has also been studied. Comparative evaluation of three medicinally used licorice species showed that *G. inflata* followed by *G. glabra* and *G. uralensis* inhibited iNOS activity in macrophage cells. In this study, isoliquiritigenin and licochalcone A strongly blocked iNOS activity, suggesting the defining role of these two compounds in the anti-inflammatory effects of licorice species (Dunlap et al., 2015). Isoliquiritigenin was also shown to modulate COX-2 and iNOS and reduce PGE2 and nitric oxide levels and also exert antiproliferative chemopreventive effects in vitro and in vivo (Takahashi et al., 2004; Lau et al., 2010).

Isoliquiritigenin has been shown to block colitis-associated tumorigenesis in animal models after 12 weeks of treatment through the suppression of PGE2 and interleukin-6 (IL-6) (Zhao et al., 2014). It was also reported that isoliquiritigenin exhibited growth inhibition and apoptosis in MCF-7 and MDA-MB-231 cells as well as in MDA-MB-231-inoculated nude mice through downregulating arachidonic acid metabolism enzymes such as COX-2 and deactivate phosphatidylinositol 3 kinase/protein kinase B pathway (Li et al., 2013b). Additionally, low concentrations of isoliquiritigenin might have breast cancer therapeutic benefits via inhibiting p38, phosphatidylinositol 3 kinase protein kinase B, and NF-κB pathways (Lorusso and Marech, 2013; Wang et al., 2013). Isoliquiritigenin inhibited phorbol ester-induced COX-2 expression in MCF-10A cells by modulating the ERK1/2 signaling pathway (Lau et al., 2010). Glabridin was reported to exert chemopreventive effects by attenuating angiogenesis via inhibiting NF-κB/IL-6/signal transducer and activator of transcription 3 signaling pathway in MDA-MB-231 and Hs-578T cells (Mu et al., 2015).

### 4. Epigenetic Pathway.

Licorice species and their related compounds have not been well studied for their potential to modulate epigenetic factors in breast cancer. It has been suggested that glabridin inhibits cancer stem cell-like properties of human breast cancer cells via modulation of micro RNA signaling (Jiang et al., 2016). In summary, licorice species have the potential to protect women from breast cancer; however, more rigorous studies with well-characterized/standardized licorice extracts are needed before recommendations of long-term use for breast cancer chemoprevention.

### H. Silybum marianum (Milk Thistle)

Milk thistle has a long tradition (2000 years) of use for liver and biliary disorders (“PDQ Milk Thistle” [http://www.cancer.gov/about-cancer/treatment/cam/hp/milk-thistle-pdq]; Abenavoli et al., 2010; Vargas-Mendoza et al., 2014). Currently, milk thistle and especially silymarin, a mixture of flavonolignans and precursor flavonoids contained in milk thistle seeds (Fig. 21), which are also used as galactagogues [Silybum marianum (Milk Thistle)], have been extensively studied as chemopreventive agents especially against hepatocarcinoma through antioxidant mechanisms (Abenavoli et al., 2010; Zapantis et al., 2012). Milk thistle could also be effective as a chemopreventive agent for breast cancer as outlined below (Agarwal et al., 2006; Malewicz et al., 2006; Cheung et al., 2010).

#### 1. Hormonal Pathway.

Weak estrogenic activities have been shown for silymarin in vivo and in vivo studies [Silybum marianum (Milk Thistle)] (Seidlova-Wuttke
The estrogenic activities of silymarin are at least in part mediated through the ERβ-receptor; silibin B, taxifolin, and quercetin show some weak ERβ estrogenic activity (Pliskova et al., 2005; El-Shitany et al., 2010; Powers and Setzer, 2015), although other studies reported no estrogenic activities for taxifolin and quercetin (Jefferson et al., 2002; Resende et al., 2013). The effect of dietary silymarin against mammary carcinogenesis was tested in a N-methyl-N-nitrosourea-induced Sprague-Dawley rat model. In contrast to the expected protective effect, the authors reported a modest increase in the number of N-methyl-N-nitrosourea-induced mammary tumors, suggesting a cautionary note for breast cancer prevention (Malewicz et al., 2006). Finally, silymarin has also been reported to inhibit aromatase activity with an IC50 of 6.7 μg/ml (Jeong et al., 1999); however, it is not known which constituents of silymarin are responsible for the aromatase inhibiting activity.

2. Chemical Pathway. Several studies report the antioxidant properties of silymarin that prevent toxin-induced liver diseases and might also block estrogen-induced genotoxicity (Vargas-Mendoza et al., 2014). Strong inhibition of recombinant P450 1A1 has been shown for dehydrosilybin (Fig. 21) (IC50 = 0.43 μM), whereas silibinin only moderately inhibited the P450 1A1 activity (IC50 = 23 μM) (Dvorak et al., 2006). Silymarin also reduced benzo(a)pyrene (BaP)-induced hepatic P450 1A/1B activity in an in vivo toxicity model (Kiruthiga et al., 2015). In addition, silymarin enhanced NQO1, sulfotransferase activities, and glutathione levels, leading to a reduction of BaP-induced toxicity in this animal model. There have been no reports on the effects of milk thistle or its bioactive compounds on estrogen metabolism.

3. Inflammatory Pathway. A number of studies support anti-inflammatory activity of silymarin and especially its major component, silibinin (Fig. 21) (Gazak et al., 2007; Deep and Agarwal, 2013). For example, silibinin treatment significantly reduced NF-κB activity, levels of IL-1β, and TNF-α in inflammatory colitis models (Esmaily et al., 2011). Silymarin also suppressed NF-κB activation by a variety of inflammatory agents in cell culture (Manna et al., 1999; Polyak et al., 2010; Kim et al., 2013a). Mechanism of action studies showed inhibition of phosphorylation of IκBα by silymarin, thus reducing NF-κB activation and nuclear translocation (Fig. 36) (Kim et al., 2013a). Downregulation of TPA-induced COX-2 by silibinin (around 50 μM) was also observed in two breast cancer cell lines (Kim et al., 2009). These results demonstrate that silibinin has several anti-inflammatory properties in cells, including breast cell lines as well as in vivo; however, further studies are necessary to determine if the high concentrations used in these studies will translate into clinical activity.

4. Epigenetic Pathway. Silymarin has not been extensively studied for epigenetic effects and no studies in breast cancer models have been reported (Gerhauser, 2012; 2013). It has been reported that silibinin (80 or 160 mg/kg BW, gavage, for 5 weeks) reduced human hepatocellular xenograft growth, which was associated with increased histone acetylation of H3 and H4, indicating their potential role in hepatocellular carcinoma growth (Cui et al., 2009). In contrast, another study described silymarin (around 500 μM) as an activator of the deacetylase SIRT1 in human melanoma cells, (Li et al., 2007; Gerhauser, 2012). Because very high concentrations were used in these studies, their translation into clinical effects is questionable. In conclusion, several in vitro studies depict that silymarin and its constituents might influence breast cancer through the hormonal, chemical, inflammatory, and perhaps epigenetic pathways; however, it is not known yet whether these effects will translate into clinical effects. Also, more studies are needed to describe the exact bioactivities of individual silymarin compounds.

I. Angelica sinensis (Dong Quai)

The dried roots of Angelica sinensis (dong quai) have been used for centuries as women’s tonic in traditional Chinese medicine, and the chemopreventive properties of this botanical are also well known (Wang et al., 2010). In Taiwan for example, 7 of the top 10 most frequently prescribed Chinese herbal products for breast cancer treatment contained dong quai (Lai et al., 2012). In traditional Chinese medicine, dong quai is usually used in combination with other herbs, and therefore many studies analyze the activity of these botanical combinations rather than dong quai and its bioactive compounds. Therefore, conclusive results about dong quai’s bioactivity are limited (Jin et al., 2016). The chemopreventive properties of dong quai, which might lead to modulation of estrogen carcinogenesis, are described below.

1. Hormonal Pathway. As mentioned in section IV. A.3.a, whether dong quai has estrogenic activities is highly controversial (Liu et al., 2001; Lau et al., 2005; Circosta et al., 2006). Some studies describe proliferative activities of a dong quai extract in MCF-7 (ERα) cells (Amato et al., 2002; Lau et al., 2005) and in BT20 (ER-negative cells) (Lau et al., 2005) and an increase in uterine weight in female Wistar rats (Circosta et al., 2006). Chang et al. (2006) demonstrated that one of dong quai’s phytoconstituents, ferulic acid (100 nM) (Fig. 10), ER dependently stimulated MCF-7 breast cancer cell proliferation, likely through upregulation of ERα-mRNA and HER2 oncogene expression. However, other investigations did not observe estrogenic activities or even described antiestrogenic effects (Zhang et al., 2005; Godecke et al., 2012). Therefore, the proliferative or estrogenic activities of dong quai might be dependent on the kind of extract, and further studies are necessary.
to delineate the estrogenic properties of dong quai and its phytochemicals. Aromatase modulating effects have not been reported for dong quai.

2. Chemical Pathway. Studies in breast cells are less known; however, phytochemicals of dong quai have been reported to modulate enzymes that are involved in estrogen metabolism. Z-ligustilide (5–50 μM) (Fig. 10) has been demonstrated to significantly inhibit BaP-induced CYP1A1 upregulation in human keratinocytes (Wu et al., 2014). Z-ligustilide (50 μM) did not activate or inhibit BaP-induced AhR translation, but it induced Nrf2 translocation and transfection of si-Nrf2 abrogated the preventive effect of Z-ligustilide on BaP-induced CYP1A1. Therefore, the authors concluded that Z-ligustilide reduced BaP-induced CYP1A1 upregulation likely through a Nrf2-mediated mechanism (Wu et al., 2014). Z-ligustilide (5–10 μM) also induced Nrf2-dependent detoxification genes, such as heme-oxygenase and NQO1 in this cell line. Similarly, other studies demonstrated that lipophilic extracts of dong quai, such as the CO2 supercritical fluid-extract, which is rich in Z-ligustilide, induced NQO1 protein and activity, ARE-luciferase activity, and Nrf2 mRNA in hepatoma cells (Saw et al., 2013). Z-ligustilide was the main compound responsible for this activity and doubled the NQO1 activity at a concentration of 6.9 ± 1.9 μM and had a chemopreventive index of 10 in hepatoma cells (Dietz et al., 2008). Mechanism of action studies showed that Z-ligustilide alkylated cysteine residues in Keap1, thus enhancing Nrf2 translation and ARE-luciferase activity (Fig. 35). This suggests that dong quai extracts that are rich in Z-ligustilide have the potential to induce detoxification enzymes and therefore might increase the detoxification of genotoxic estrogen metabolites (Fig. 34).

3. Inflammatory Pathway. Various in vitro and in vivo studies analyzed the inflammatory activity of dong quai and its phytochemicals. For example, the lipophilic supercritical CO2 extract of dong quai (1.1–17 μg/ml), which is rich in Z-ligustilide, and Z-ligustilide itself (6.3–50 μM) suppressed LPS-induced NO production in macrophages (RAW 264.7 cells) (Saw et al., 2013). The extract (17 μg/ml) also significantly inhibited LPS-induced IL-1β in these macrophages. The volatile oil of dong quai (0.176 ml/kg BW) inhibited LPS-induced acute inflammation in a rat model (Li et al., 2016). Specifically, the oil decreased the levels of proinflammatory cytokines, such as TNF-α and IL-1β; inflammatory mediators, such as PGE2 and NO; the inflammation-related enzymes (iNOS and COX-2); and promoted the production of the anti-inflammatory cytokines IL-10. Z-ligustilide (5–25 μM), one of the most abundant ingredients in the volatile oil, also significantly suppressed the production of NO, iNOS, PGE2, and TNF-α in LPS-induced inflammation in macrophages (RAW 264.7) (Su et al., 2011). Mechanism of action studies demonstrated that Z-ligustilide decreased the phosphorylation of IKK, thus reducing the cytosolic degradation of IκBα and decreasing nuclear activation of NF-κB (Fig. 36). In addition to its anti-inflammatory effects, Z-ligustilide also significantly reduced reactive oxygen species in this cell line. Not only Z-ligustilide (IC50 = 25 μM), but also another compound in dong quai, ferulic acid (IC50 = 10 μM) (Fig. 10), inhibited NF-κB luciferase activity in LPS and interferon-γ-stimulated murine macrophages (Chao et al., 2010) as well as decreased hydrogen peroxide-induced IL-1α and TNF-α mRNA in porcine chondrocytes (Chen et al., 2010a). An ethyl acetate extract of dong quai, which contains both compounds as major constituents, significantly reduced inflammatory markers, such as TNF-α, in vitro (concentrations ≥5 μg/ml) and in vivo (1.56 mg/kg BW tube feeding for 1 week before LPS injection) inflammation models (Chao et al., 2010).

4. Epigenetic Pathway. There are very few studies on the influence of dong quai and its constituents on epigenetic pathways. Z-ligustilide (50 μM) and the supercritical CO2 fluid extract of dong quai (8.5 μg/ml) significantly decreased the relative amount of methylated DNA in the Nrf2 gene promoter region, thus leading to enhanced Nrf2 mRNA and protein expression as well as to upregulation of its downstream target genes in TRAMP C1 prostate cancer cells (Su et al., 2013; Guo et al., 2015b). In conclusion, several studies suggest that dong quai and its compounds, mainly Z-ligustilide and ferulic acid, might have the possibility to modulate estrogen carcinogenesis; however, conflicting data of dong quai on its effect of the hormonal pathway as well as limited data on its influence on estrogen metabolism and epigenetic pathways warrant further investigations before clinical studies can be performed.

J. Others

As mentioned in section IV.A.2.g, Epimedium species have a long history in treating sexual dysfunction and osteoporosis in traditional Chinese medicine and recent studies suggest chemopreventive properties (Ma et al., 2011). The aglycone icaritin and its metabolite des-methylcaritin (Fig. 30) demonstrated proliferative activities (1 nM–10 μM) in breast cancer cells, MCF-7, potentially enhancing hormonal estrogen carcinogenesis (Wang and Lou, 2004). However, at higher concentrations (>1 μM), icaritin inhibited estradiol induced MCF-7 cell proliferation (Tiong et al., 2012). Mechanism of action studies revealed that icaritin as an AhR agonist leads to destabilization of the ERα protein and to subsequent reduction of estrogenic responses. This activity was confirmed in an in vivo model, in which icaritin treatment (10 μmol/kg every 2 days for 9 weeks, i.p.) reduced ERα protein levels and estradiol-stimulated breast cancer xenograft growth. Similarly, administration of the highest dose of an Epimedium extract (5 g/kg) to ovariectomized athymic nude mice that
were inoculated with MCF-7 breast cancer cells reduced ethinyl estradiol-induced xenograft growth and ER{α} protein content (Indran et al., 2014). None of the concentrations induced mammary tumors and only the lowest concentration of Epimedium extract (500 mg/kg BW) induced uterine weight, suggesting that lower concentrations might be estrogenic and higher concentrations reduce estrogenic responses through destabilization of ER{α}. Icaritin might also have the potential to modulate estrogen metabolism, because icaritin has been shown to compete with TCDD at the AhR (IC_{50} ≈ 1 μM) and to induce CYP1A1 (Tiong et al., 2012). Moreover, investigations with a water extract of herba Epimedi demonstratae anti-inflammatory activities in macrophages as well as in an in vivo inflammation model (Oh et al., 2015). The extract inhibited NF-κB activation and thus reduced iNOS and subsequent NO formation as well as reduced IL-6 and IL-1β. It also induced the detoxification enzyme heme oxygenase. Overall, these studies show that herba Epimedi might have the potential to modulate estrogen carcinogenesis; however, more studies describing details of the different extracts and influence on different estrogen metabolism enzymes are necessary to assess its overall effect on estrogen carcinogenesis. Chemopreventive properties have also been described for ginger and for flaxseed, which are likely due to antioxidant, anti-inflammatory, and induction of detoxification genes (Gan et al., 2013; Mason and Thompson, 2014). Clinical trials are needed to establish safety and efficacy (Baliga et al., 2011). In conclusion, many women’s health botanicals have the potential to influence estrogen carcinogenesis through multiple pathways. However, more studies are needed to delineate the exact effects on different pathways and to standardize the extracts for further clinical studies.

VI. Botanicals/Phytochemicals with Potential Toxic Effects

Most botanicals used for women’s health have a long history of ethnobotanical use and are generally considered safe (van Breemen et al., 2008). However, it is important for women and their health practitioners to remember that most botanicals have not been rigorously tested for potential toxic effects, unlike FDA approved drugs. Some case studies of hepatotoxicity in particular have been reported for these botanicals (e.g., black cohosh), although these seem to be rare and probably the result of other health-related issues (Mahady et al., 2008; Teschke et al., 2013). Botanical-drug interactions could also lead to toxicity through drug overdoses or decreased drug efficacy, and these effects are briefly reviewed below. More comprehensive reviews were recently published (van Breemen, 2015; Sprouse and van Breemen, 2016).

Because of the popularity of botanical dietary supplements (Lindstrom et al., 2014; Smith et al., 2015), it is likely that many consumers use herbal products together with other drugs. This is particularly noteworthy, because many users of botanical products do not mention the use of dietary supplements to their health care providers. Some prescription drugs, such as warfarin and digoxin, have a narrow therapeutic index and therefore botanical/drug interactions with these drugs could have detrimental consequences (de Lima Toccafondo Vieira and Huang, 2012). In fact, studies showed that around 20–25% of all prescription drug users take herbal medicines concomitantly with conventional medications (Shord et al., 2009; de Lima Toccafondo Vieira and Huang, 2012). Because of the concurrent use of botanical products and prescription drugs, pharmacokinetic (de Lima Toccafondo Vieira and Huang, 2012; Gurley et al., 2012; Sprouse and van Breemen, 2016) and pharmacodynamic botanical-drug interactions (de Lima Toccafondo Vieira and Huang, 2012) are possible (Kennedy and Seely, 2010). The pharmacokinetic and pharmacodynamic botanical-drug interactions were reviewed recently in detail (Colalto, 2010; de Lima Toccafondo Vieira and Huang, 2012; Gurley et al., 2012; Sprouse and van Breemen, 2016). Therefore, mainly the major potential botanical-drug interactions based on pharmacological interferences of the aforementioned women’s health botanicals/phytochemicals will be briefly reviewed.

Most of the reported drug-botanical interactions are due to interference with metabolism (pharmacokinetic effects). For example, cranberry juice was shown to inhibit the metabolism of the probe P450 3A4 substrate midazolam in healthy volunteers (Kim et al., 2011). Silybin was reported to inhibit P450 3A4 and 2E1 (Sprouse and van Breemen, 2016), although no effect of milk thistle extract on P450 3A4 activity was observed in a small clinical trial (Gurley et al., 2006). The same trial showed no effect of black cohosh on P450 3A4 activity. Similarly, there was no effect of valerian on marker substrates of P450 3A4, 1A2, 2E1, and 2D6 (12 volunteers, 375 mg/day, administered for 28 days) (Gurley et al., 2005; Colalto, 2010). Another clinical trial with 12 healthy volunteers showed induction of P450 3A4 after silymarin treatment (140 mg/day, 9 days) (Rajnarayana et al., 2004; Colalto, 2010). Mild pharmacokinetic interactions have also been described for licorice (Sprouse and van Breemen, 2016). The current information suggests that concomitant intake of botanicals used for women’s health are not a major risk for drugs that are metabolized by P450s (Zadoyan and Fuhr, 2012); however, health practitioners should monitor potential drug/botanical interactions in their patients.

Some botanical drug interactions are due to pharmacological interactions. Chasteberry may interact with
drugs that antagonize the dopamine receptors and with oral contraceptive drugs (Daniele et al., 2005). Case reports describe that patients who took the anticoagulant warfarin (Fig. 38) together with Angelica sinensis (dong quai) extracts have an increased prothrombin time and showed widespread bruising (Fugh-Berman, 2000). Therefore, patients with clotting disorders or those that undergo anticoagulant therapy should be cautious with the concurrent use of dong quai products. The reason for the reported anticoagulant effect is likely that dong quai contains various coumarin derivatives (Fig. 38) that, like warfarin, inhibit the release of plasma clotting factor VII by vitamin K (Lowenthal and Birnbaum, 1969; Head, 2004). A caveat of these case reports is that the extract and specific phytochemicals are not well characterized (Fugh-Berman, 2000). Therefore, more research is warranted to delineate any potential interactive compounds as well as to use standardized extracts that give a consistent activity without showing drug interactions.

Licorice may lead to botanical-drug interactions and side effects after long-term use due to the sweet saponin compound, glycyrrhizin (or glycyrrhizinic acid), which is metabolized after oral administration to glycyrrhetinic acid (Fig. 27) (Fugh-Berman, 2000; Kao et al., 2014). Glycyrrhizin and especially glycyrrhetinic acid are...
potent inhibitors of the enzyme 11β-dehydrogenase, which is involved in the metabolism of cortisol (Kao et al., 2014). As a consequence, long-term usage of licorice products may lead to increased cortisol plasma levels, resulting in sodium retention, hypokalemia, edema, that may eventually lead to hypertension and heart disease (Kao et al., 2014). When licorice is concurrently used with corticosteroid drugs, such as hydrocortisone or prednisolone, the corticosteroid treatment can be potentiated through licorice products (Teculescuingh et al., 1990; Fugh-Berman, 2000). A case report described profound hypokalemia after ingestion of small amounts of licorice contained in a laxative preparation taken together with an antihypertensive drug (not specified in the article) (Izzo et al., 2005). Because some antihypertensives and licorice may lead to an increase in potassium excretion, the combination might have led to an additive effect. Hypertension, edema, and hypokalemia were also reported after concurrent use of oral contraceptive and licorice products (Fugh-Berman, 2000). In addition to these adverse effects, glycyrrhizin and glycyrrhetinic acid have been reported to show many beneficial bioactivities that have been ascribed to licorice, such as anti-inflammatory, chemoprotective, antiulcerogenic, secretolytic, antiviral, and antimicrobial activities (Liu et al., 2013; Kao et al., 2014; Wang et al., 2015a).

VII. Conclusions and Future Directions

Figure 39 summarizes the multiple effects of women’s health botanicals described in this review. As women age, their botanical use changes from occasional use for UT infections, PMS, nausea associated with pregnancy, and lactation issues to more frequent use for meno-pausal symptoms, osteoporosis, and premenopause. Because botanicals are from natural sources they are perceived as harmless, although there are only a few studies on safety let alone efficacy. The increasing popularity of botanical supplements for women’s health as well as the aging population requires rigorous clinical trials with standardized botanicals to determine efficacy. The effect of botanicals on hormone balance is likely dependent on age, and yet little information is available on efficacy in younger women versus older women. It is crucial that botanicals be fully standardized to botanical, phytochemical, and biological properties. In addition, the pharmacokinetic and distribution profile of the active constituents have to be determined to reach safe and efficacious concentrations in a clinical setting. Potential genetic polymorphisms in metabolism especially with the gut microbiota could have dramatic effects on the absorption and efficacy of botanicals. Drug-botanical interactions must be determined to avoid potentially toxic side effects or loss of activity of prescription drugs. Women must be encouraged to discuss their use of botanicals with their health care providers for assistance in managing all aspects of their health throughout their lives.

Acknowledgments

We very much appreciate the photographs of the plants in Fig. 1 provided by Dr. Doel Soejaarto and Dan Lu, assistance with figures from Christina Sidorowycz, and the helpful discussions with Dr. Richard van Bremen and Dr. Dejan Nikolic.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Dietz, Hajirahimkhun, Dunlap, and Bolton.

References


Phytochemicals for Women's Health


López-Bermejo N, Gil-Navarro G, Rodríguez H, and Amezúa FJ (2014) Identification and quantification of the main isoflavones and other phyto-


Medjakovic S and Jungbauer A (2008) Red clover isoflavones biochanin A and for-


cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345:d6409.


